

Treatment decisions with greater certainty

ANNUAL REPORT **2023/2024**

BIOVICA®

Contents

Production: Biovica International AB in collaboration with Cord Communications & Meze Design.
Photographs: Cover: Shutterstock. Insert: Alex Giacomini, Lilla Produktionsbolaget, Christoffer Dracke and Shutterstock.

Commercialization of DiviTum® TKa in the USA began during the financial year.

2023/2024 IN BRIEF

Q1 – First quarter

- First commercial agreements in the USA signed with MediNcrease Health Plans, Contigo Health ConfigureNet™ provider network and Occum Health.
- Results from the SWOG study (S0226) presented at ASCO.
- PLA code for Medicare received.

Q2 – Second quarter

- CAP accreditation obtained for CLIA laboratory in San Diego.
- Additional agreements signed in the USA with, among others, world-renowned cancer clinic in Florida and leading caregivers in both Missouri and Arizona.
- Prospective clinical trial with Yale Cancer Center announced.

Q3 – Third quarter

- Commercial agreements signed with Axlab in the Nordics and Palex Group in Spain and Portugal.
- DiviTumTKa received pricing decision from Medicare.
- Licensed obtained for state of Maryland.
- Rights issue raised capital of SEK 100 million prior to issue costs.
- DiviTum TKa featured in three posters at the world's largest breast cancer symposium, SABCS.

Q4 – Fourth quarter

- Master service agreement for TKa testing signed with leading pharmaceutical company and biopharma company.
- Interventional trial launched at Washington University.
- Positive patent notification for immunotherapies.
- Observational trial started at Mayo Clinic in Florida.
- Cost reduction program implemented in Sweden and the USA.

Events after the end of the period

- DiviTum TKa results presented at ASCO, the world's largest cancer conference.

Biovica in brief

Biovica develops and commercializes the blood-based biomarker assay, DiviTum TKa , which is used to evaluate the effect of cancer treatments. DiviTum TKa has successfully demonstrated its capabilities to early evaluate therapy effectiveness in several clinical studies. The initial area for clinical use of DiviTum TKa is monitoring the treatment of metastatic breast cancer. It is an area where there is a great need for better biomarkers so that physicians are more quickly and effectively able to monitor how each individual patient is responding to treatment.

The launch of DiviTum TKa in the USA began during spring 2023. DiviTum TKa was also simultaneously introduced via partners in the European markets of Italy, the Netherlands, the Nordics, Poland, Portugal and Spain. Biovica is prioritizing the five largest, most populous countries in Europe along with the Nordics. More long term, Biovica intends to launch DiviTum TKa in additional markets (such as Japan) and for the treatment of other types of cancer and new targeted therapies. It is also being developed as a prognostic tool for treatment outcome.

And, together with pharmaceutical companies, Biovica is striving to ensure that the technology behind DiviTum TKa becomes part of Companion Diagnostics (CDx) tests, which match a patient to a specific drug or therapy. Biovica has several collaboration agreements in place with pharmaceutical companies that are using DiviTum TKa to develop new drugs for cancer treatment.

For the 2023/2024 financial year, Biovica's sales amounted to SEK 7.3 million and the company had 32 employees as of the end of the period. The head office, where R&D and production occurs, is located in Uppsala, Sweden. Biovica also has an office and laboratory in the USA, in San Diego, California. In 2017, Biovica's shares became listed on Nasdaq First North Growth Market Stockholm and in 2019, the listing changed to Nasdaq First North Premier.

DiviTum® TKa

BREAST CANCER

DiviTum TKa

DiviTum TKa is a dynamic biomarker test which, in several studies, has demonstrated its ability to provide answers about how a patient is responding to cancer treatment. Because all that is required of the patient is a simple blood sample, it is possible to, easily and frequently, evaluate the treatment.

The level of TK activity, measured by DiviTum TKa , is closely correlated with cell proliferation. Because of that, monitoring TK with a biomarker is a suitable way of evaluating tumor aggressiveness and disease progression when, for example, patients are being treated with a CDK 4/6 inhibitor.

Measuring TK activity with DiviTumTKa provides a quick and precise evaluation of how a patient is responding to a particular type of cancer treatment. The information is clinically useful and it enables doctors to tailor and optimize treatment so that the patient gets the best possible outcome and unnecessary costs of care can be avoided.

Metastatic breast cancer

Breast cancer is usually expressed as a number on a scale of 0 through IV, depending on how large the tumor is and whether or not it has spread.

Metastatic breast cancer is stage IV, which means that the original (primary) tumor has traveled through the blood or lymph system to form new tumors (metastases) in other organs or tissues of the body, typically in the skeleton, liver, brain or lungs.

Biovica's history

In 1982, Uppsala researchers ***Simon Gronowitz*** and ***Claes Källander*** discovered the method for measuring thymidine kinase, which was later patented. In 2005, the first version of the assay received CE marking and the first clinical collaborations were initiated.

In 2013, Karolinska Institute published the first clinical study with DiviTumTKa and in the years that followed, important collaborations were set up with leading researchers at, for example, Dana Farber Cancer Institute, Washington University, International Breast Cancer Study Group (IBCSG), BIG against breast cancer, Mayo Clinic and Johns Hopkins University.

Since 2016, the results from clinical studies with DiviTumTKa have been presented each year at San Antonio Breast Cancer Symposium (SABCS), which is the world's largest breast cancer symposium.

DiviTumTKa an early biomarker



DiviTumTKa can quickly reveal whether or not treatment is effective.

Biovica's mission is to transform how cancer treatments are monitored by offering innovative biomarker assays.

The initial focus on metastatic breast cancer facilitates a cost-effective launch of the assay in an area where there is a great need.

Biovica's vision is to improve the lives of cancer patients

Vision

Biovica's vision is to improve the lives of cancer patients.

Mission

Biovica's mission is to transform how cancer treatments are monitored by offering innovative biomarker assays.

Strategy

Theoretically, DiviTumTKa can be used for all types of cancer, but Biovica has initially chosen to focus on its use for monitoring the treatment of metastatic breast cancer. The initial market launch of DiviTumTKa is in the USA, which has attractive reimbursement levels and is also the world's largest market.

DiviTum technology is also being used by pharmaceutical companies to develop Companion Diagnostics (CDx).

Biovica's strategy is implemented in three steps:

1. Demonstrate the value of the product via the results from clinical collaborations with Key Opinion Leaders and academic institutions
2. Launch via own CLIA laboratory in the USA and through partners in Europe, as well as pharma collaborations to develop Companion Diagnostics (CDx).
3. Expansion into other parts of the world and application areas

Business concept

To develop and commercialize blood-based biomarkers that improve monitoring and evaluation of modern cancer treatments.

Business model

DiviTumTKa has obtained market approval in the USA and EU and is being used in clinical routines. In the USA, it is offered as an analysis service via Biovica's wholly owned laboratory. For sales and analysis in the EU, Biovica is using partners.

DiviTum technology is also being used by biotech and pharmaceutical companies to develop Companion Diagnostics (CDx), which are market-approved tests or devices sold together with a particular drug to monitor its effect.

In addition, DiviTumTKa is sold to pharmaceutical companies and academic institutions for use in clinical studies with the aim of developing new cancer treatments or improving existing ones. The product is either sold as a service (analysis and consultation) or as an analysis kit for the customer's laboratory.

Sales efforts are yielding results

Biovica made significant progress with sales during the 2023/2024 financial year. Positive points to highlight are the sales trend in the USA and progress with Pharma Services. Our efforts to introduce DiviTumTKa to the US market are beginning to yield results in the form of higher sales. The trend from the third quarter persisted and further strengthened during the fourth quarter. In total, we have now surpassed the milestone of SEK 1 million in sales in the US market since the assay was launched in 2023.

For the entire fiscal year, our sales were SEK 7.3 (3.4) million. It is more than twice the level last year, albeit under our goal of SEK 10 million, which we are obviously not satisfied with. The positive trend during the last two quarters bodes well for the coming quarters and we are still set on achieving our goal of sales growth that makes the company cash flow positive during the second half of 2025. It is an extremely important goal for Biovica particularly in light of the fact that the cost of capital has so sharply increased.

This was also the reason for our decision in April to implement a cost reduction program whereby the company will save SEK 30 million per year, with an associated restructuring cost of SEK 8 million. We are retaining most of our sales force and they continue to cultivate our customers with good results.

The feedback from our sales force, who are meeting with oncologists on a daily basis, is very positive. Oncologists who treat patients with CDK inhibitors – the standard treatment for metastatic breast cancer – see a great need for a tool that helps them monitor their patients and assess whether the treatment is effective or not. An ever-increasing number of oncologists are placing regular orders for DiviTum TKa. We are also receiving regular reports that DiviTum TKa significantly improves clinical routines and benefits patients by being able to assure them that the prescribed treatment is working, which also helps them endure any difficult side effects. If the treatment they are on is not having the desired effect, they can be offered an alternative treatment more quickly, or a dosage that is more tailored to their needs.

The FDA initiative called Project Optimus also puts more emphasis on dose optimization. It is aimed at reforming and improving dose optimization, i.e. the dosage that yields the best effect with the least side effects, which increases the demand for biomarkers like DiviTum TKa.

We achieved an important milestone during the year when the Centers for Medicare & Medicaid Services (CMS) set the price of DiviTum TKa at USD 322 per test, effective as of 1 January 2024. With this decision and the fact that agreements in the private sector are at a significantly higher price, the prerequisites are good for achieving an average price that is on a par with, or slightly above, USD 400 per test, which is what we have previously communicated as our goal for the US market. It also means that we will be reimbursed at good levels for patients covered by Medicare. They represent around 50 percent of the patient group that we focus on for the use of DiviTum TKa in the area of metastatic breast cancer. Besides Medicare, we have signed six commercial agreements covering more than 50 hospitals, which clearly demonstrates the potential of DiviTum TKa. DiviTum TKa definitely has a need to fill.

Our sales in the USA during the fourth quarter of the financial year were larger than the accumulated sales of the previous three quarters and the number of unique patients nearly doubled. In Europe, our goal for quite some time has been to sign partnership agreements in the most populous countries, as well as in the Nordics. We already had agreements signed for Italy, the Netherlands and Poland and we made significant progress during the year by signing agreements for Spain, Portugal and the Nordics. Our partnership agreements in Europe give us access not only to a sales force, but also laboratories that perform analyses.

Our clinical collaborations with academia also progressed during the year. For example, an observational trial with DiviTum TKa at Mayo Clinic in Florida was initiated, as well as the clinical trial, BettER, that was launched at Washington University School of Medicine in St. Louis. A prospective clinical trial also got underway at Yale Cancer Center, which is investigating the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of metastatic breast cancer patients. The study at Yale is aligned with the FDA initiative, Project Optimus, aimed at reforming and improving dose optimization, which means moving from maximum tolerated dose (MTD) to minimum effective dose (MED). This is fueling an even greater need for good biomarker assays that can be used to evaluate treatment effect.

The study at Mayo Clinic involves 100 patients to investigate the potential of DiviTum TKa as a predictive biomarker. BettER is an interven-

We made significant progress and achieved many important milestones during the past year.

ANDERS RYLANDER
CEO

tional trial aimed at using biomarker-driven insights to adapt therapies and reduce unnecessary toxicity, thereby improving patient outcomes. If successful, it will strengthen our argument for including DiviTum TKa in clinical guidelines and payment systems. Summaries of study results where DiviTum TKa has been used were published at both the world's largest and most important breast cancer conference, the San Antonio Breast Cancer Symposium (SABCS) and the world's largest cancer conference, the American Society of Clinical Oncology (ASCO) during the financial year, which attests to the quality of those results.

These studies supplement our already strong documentation and contribute to the desired outcome of having DiviTum TKa included in clinical guidelines and payment systems.

During the year, we also received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker for immunotherapies. In addition, the European Patent Office (EPO) has concluded that all our claims are novel and innovative, which paves the way for a quicker patent process in Europe. An approved patent makes it possible to create unique, protected value propositions in an area that greatly benefits patients and opens up possibilities for expanding Biovica's market potential even more.

Rapid developments are happening in the area of cancer diagnostics and treatments, all of which is positive for Biovica given the increasing focus on personalized medicine and biomarker-driven treatments. The trends are aligned with our efforts, making us well positioned thanks to DiviTum TKa. We made significant progress within the company during the year and there are many external factors impacting Biovica and DiviTum TKa in a positive way.

At the same time, there are challenging factors in the outside world that could negatively impact the company, such as regulatory changes, the competitive situation and economic factors that could impact the company's operations, financing and strategic plans. We are still being impacted by the persistent high interest rates, which has lowered the risk appetite of investors. Focusing on sales and keeping costs down is the best way for us to meet those challenges. Thanks to the enormous dedication of our employees, we have continued to develop the business despite these challenging times.

The rights issue during the third quarter makes it possible for us to continue building on the good start for DiviTum TKa in the USA and Europe, along with expanding our cooperations in the pharmaceutical industry. We are dedicated to creating value for patients with metastatic breast cancer and for our shareholders.

Anders Rylander, CEO

Large clinical need and market potential

It is estimated that approximately 450,000 patients in the EU and the USA are currently living with metastatic breast cancer. Breast cancer is responsible for more than 40,000 deaths each year in the USA alone[1]. These deaths happen because the disease has spread through the body and affected critical organs. Of those diagnosed for the first time with breast cancer, the cancer has already started to spread for three to five percent of them. If the cancer has spread, it is incurable. However, new treatments have been developed in recent years that extend the time that a patient can live with metastatic breast cancer. The number of available treatments has also risen. Metastatic breast cancer is currently a chronic illness that requires lifelong treatment. Around 29 percent of patients live more than five years with the disease[2].

For patients who are diagnosed with hormone receptor-positive breast cancer, the treatment outcome has primarily been improved through a combination of endocrine therapy and a CDK 4/6 inhibitor to slow down the cell cycle, which counteracts proliferation (cell division) and inhibits the growth of cancer cells. Approximately 80 percent of all breast cancer patients have hormone receptor-positive cancer.

As more and better treatments become available, it becomes increasingly important for doctors to know, with greater certainty, when it is time to switch from one treatment to the next, or when to transition from endocrine treatment to cytostatic drugs/chemotherapy. Many patients do not respond to treatment or they develop resistance, which is difficult to discover without reliable tests. Furthermore, there is a great need for being able to more easily and quickly evaluate the effect of treatment. Besides that, many cancer treatments involve serious side effects and there are financial incentives because the treatments are expensive, costing more than USD 10,000 per patient and month.

A number of tests and methods are run repeatedly and regularly to assess how the disease is progressing. In most instances, a single test will not provide a definitive answer, which is why many different tests are run repeatedly. Current diagnostic procedures are expensive, complicated and require time for monitoring, which is sub-optimal for the healthcare system and stressful for patients.

The initial target group for DiviTum TKa is women with hormone receptor-positive metastatic breast cancer who are being treated with endocrine therapy. Each year in the USA alone, there are about 31,000 new patients for whom DiviTum TKa could be part of their treatment monitoring. Patients generally remain in this population for up to three lines of treatment, often for three years or longer.

External advisors and oncologists suggest that a blood-based test such as DiviTum TKa could be used as frequently as monthly early on during a treatment, and every three months thereafter. With testing frequency as suggested here, it corresponds to a market opportunity of 755,000 tests/year for metastatic breast cancer in the USA. For hormone receptor-positive breast cancer, Biovica estimates that the market potential is USD 400-700 million per year for DiviTum TKa in the USA, EU-5, Nordic countries and Japan. The market potential will likely also grow as new treatments lengthen patient lives even more.

One of the strongest trends in cancer treatment and monitoring is personalized medicine, where various biomarkers are used to tailor treatment strategies for defined patient groups. It is a favorable trend for Biovica, since it raises the interest in biomarkers with monitoring potential.

1. www.breastcancer.org/facts-statistics 2. www.cancer.net/cancer-types/breast-cancer-metastatic/statistics

Launch in the **USA (1)** followed by launch in **Europe (2)**, where Biovica is prioritizing the five largest, most populous countries in the EU along with the Nordics. During the 2023/2024 financial year, partnership agreement were signed for the Nordics, Portugal and Spain. Biovica now has partners in Italy, the Netherlands, the Nordics, Poland, Portugal and Spain. More long term, Biovica also intends to launch in **Japan (3)**.

These three markets have a total potential of USD 400– 700 million per year for metastatic breast cancer. Besides that, there is additional potential elsewhere in the world and for other forms of cancer.



NEW PATIENTS EACH YEAR IN THE USA

31,000 PATIENTS FOR WHOM DiviTumTKa COULD BE USED TO MONITOR TREATMENT

MARKET POTENTIAL FOR METASTATIC BREAST CANCER IN THE USA

755,000 TESTS PER YEAR

MARKET POTENTIAL FOR METASTATIC BREAST CANCER IN THE USA, EUROPE AND JAPAN

400-700 USD MILLION PER YEAR

Commercialization in the USA

During the 2023/2024 financial year, Biovica made significant progress in the US market. Among others, Biovica obtained a unique PLA code and pricing decision by Medicare for DiviTum TKa , both of which are important to the commercialization efforts.

With 510(k) clearance, a unique PLA code, Medicare price and, not least our own CLIA lab, Biovica has put many of the prerequisites in place for a continued successful launch in the USA. The six commercial agreements that Biovica already has in place cover around 50 hospitals, which is evidence of the assay's potential.

Since 1 October 2023, Biovica has had a specific code for DiviTum TKa issued by the AMA (American Medical Association). It enables payers and providers to easily identify our product and reduces the administrative burden on them. It is used for invoicing, reporting and processing of healthcare claims, which means that Biovica's process for pricing by Medicare has been accepted by state and commercial payers in the USA in their contract and advertising processes.

In December 2023, Biovica obtained a license for the state of Maryland. In terms of population, it is the 18th largest state in the USA. The license enables Biovica to receive, test and report patient samples from all states in the USA except New York and Washington D.C. The coverage is thus 49 states and 94% of the US population, which is equivalent to 311 million residents.

Starting on 1 January 2024, Biovica will receive USD 322 per test from the Center for Medicare & Medicaid Services (CMS). Pricing is extremely important, since Medicare patients represent half of the available market for DiviTum TKa in the USA. The pricing decision also means that there is a high probability to deliver in line with, or even above, the average price of 400 USD per test that has previously been communicated, since established agreements with private actors are significantly higher in price.

CLIA-certified and CAP-accredited laboratory in San Diego

Biovica's laboratory in the USA is located in San Diego, California. It processes and reports back on the samples it receives from patients, as well as on the clinical samples it receives from pharmaceutical partners and researchers. Certification as per the Clinical Laboratory Improvement Amendments (CLIA) is issued by the Center of Medicare and Medicaid Services (CMS). Laboratories must be CLIA-certified before they can accept human samples for testing and report the results. It also received accreditation from the College of American Pathologist (CAP) in October 2023. CAP accreditation is awarded to laboratories that meet stringent requirements and maintain the highest standards for laboratory operations in terms of quality, accuracy, and consistency, as outlined by CAP. The laboratory has also been approved as a Medicare supplier, which means that Biovica may now invoice for its services and can start the certification process for individual state Medicaid programs.

The initial target group for DiviTumTKa is women with hormone receptor-positive metastatic breast cancer who are being treated with endocrine therapy. Each year in the USA alone, there are about 31,000 new patients for whom DiviTumTKa could be part of their treatment monitoring.

LOCALLY ADVANCED CANCER

A higher rate of cell growth applies to all types of cancers and many cancers are treated with drugs that specifically target cell division. Biovica intends to expand the use of DiviTumTKa to some of these other indications after the launch for metastatic breast cancer. Locally advanced cancer is a natural choice, since it is expected that the treatments used for metastatic cancer will also be used for locally advanced cancer. The needs are therefore similar. Locally advanced cancer adds another 30-40 percent market potential in existing markets.

COMMERCIAL AGREEMENTS

Early in the financial year, Biovica signed its first commercial agreements in the USA. The first one is with MediNcrease Health Plans, which is a nationwide U.S. supplier network and professional association. It makes the assay available and reimbursable to more than 15 million policyholders in the USA. The second is with Contigo Health ConfigureNet™. It is a supplier network with more than 900,000 representatives at 4.1 million locations in the USA. It makes the assay available to tens of thousands of Contigo Health policyholders in the USA. By the end of the financial year, Biovica had signed 6 commercial agreements and around 15 customers are regularly ordering the test. These commercial agreements serve as evidence to potential partners of the significant benefits that DiviTum TKa offers to patients, caregivers and payers.

FACTORS FOR A SUCCESSFUL LAUNCH

- Results from clinical studies demonstrating the value of DiviTumTKa.
- Inclusion in treatment guidelines.
- Inclusion in reimbursement systems.
- Informing and educating oncologists so that they understand the advantages and decide to use DiviTumTKa because it provides important information about the patient's disease status.



DURING THE FINANCIAL YEAR, BIOVICA SIGNED PARTNERSHIP AGREEMENTS FOR THE NORDICS, PORTUGAL AND SPAIN.

2023/24

AGREEMENTS HAD ALSO BEEN SIGNED IN ITALY, THE NETHERLANDS AND POLAND PRIOR TO THIS FINANCIAL YEAR.

Our commitment to DiviTumTKa reflects our strong determination to provide health professionals and their patients with disruptive solutions capable of improving people's lives.
In this case, with a non-invasive solution that allows prognosis and monitoring the effectiveness of treatment for advanced cancer patients treated with CDK4/6 inhibitors

XAVIER CARBONELL
CEO OF PALEX GROUP

Making therapeutic decisions in a timely manner is vital in order to optimize patient treatment and increase survival. Having new non-invasive tools capable of personalizing treatment with high-impact drugs such as CDK4/6 inhibitor is a revolutionary opportunity.

CARLOS HAGEN
MEDICAL DIRECTOR
OF ONCOLOGY AT PALEX

Bringing DiviTumTKa assay to the Nordics perfectly fits our organization. We have access to a multi-functional medical network around cancer patients at the hospitals and a deep experience in oncology healthcare processes. The DiviTumTKa assay strengthens our market position further and brings us closer to the goal of delivering patient-centric treatment monitoring.

SØREN CHRISTENSEN
CEO OF AXLAB

Commercial success and launch in Europe

To ensure a successful market penetration, DiviTumTKa is being introduced in selected markets via partners. The company has already partnered with some companies that have documented success with sales in the area of oncology and it is working to set up more in markets that address the overall situation of a cancer patient.

Partners for the commercialization in Europe

The partners that Biovica decides to collaborate with must have a recent track record of strong sales, success in getting new products included in reimbursement systems, and an established network of payers.

In January 2024, Biovica signed a collaboration agreement for Spain and Portugal with Palex Group, which is a leading supplier of hospital equipment. It also has an excellent track record in commercialization of oncology tests and surgical instruments in southern Europe. This collaboration makes the assay available to the more than 8,000 patients who are diagnosed with metastatic breast cancer each year in Spain and Portugal.

In November 2023, Biovica signed a collaboration agreement for the Nordics with Axlab A/S. It is one of five leading companies for cancer screening and diagnostics in the Nordics. In the Nordics, approximately 5,700 women are diagnosed with metastatic breast cancer each year. Based on the number of patients with metastatic breast cancer, the Nordic countries represent around 6% of the total market potential for the combined area of EU5 and the Nordics.

Axlab and Palex will be leading the market introduction, with a focus on creating high awareness and knowledge among breast cancer doctors and other relevant decision makers, as well as incorporating the test into clinical guidelines.

Simultaneous to our efforts to sign additional partnership agreements, Biovica is involved in a variety of activities for reimbursement in each European country, thereby recognizing the full potential that exists in the EU over time. Support from local KOLs in the field of breast cancer will also be an import success factor for the launch in each market.

Biovica will gradually be launching the product in other parts of Europe. Markets with a medium-high to high price level and reimbursement systems that allow hospitals to set their own budgets, such as the Nordic countries and Spain, are attractive for clinical, routine use of DiviTum TKa. Biovica's European expansion strategy is based on a gradual market introduction, which will enable the company to learn from experiences in the first countries where the product is launched and prepare for the next level of expansion.

Because DiviTum TKa has CE-IVD marking, the product may be sold throughout the EU, as well as in the UK and Norway, both of which accept this as the regulatory framework for clearance there. Biovica now has collaborations established in five important markets and expects to set up more in Europe.

INTERVIEW CEO OF AXLAB, SØREN CHRISTENSEN

We are excited about the opportunities that lie ahead for us and committed to advancing the care of cancer patients through innovation and collaboration.

SØREN CHRISTENSEN
CEO OF AXLAB

Could you tell us more about Axlab and your role in the market?
Axlab was founded in 1993. It is a Danish pathology company that has expanded its operations to other Nordic countries during the last 30 years. Our motto is "your vision, our inspiration". It reflects our commitment to helping our customers achieve their goals, particularly when it comes to publicly funded care. We are proud of being a true partner that is deeply involved in various healthcare processes and segments. We understand the ever-changing healthcare market and have a track record of driving innovation through strategic partnerships like the one we have with Biovica.

How did the collaboration with Biovica come about?
Our collaboration with Biovica was a result of long-term relationships and discussions. When Biovica was ready to proceed with the commercialization, it was a natural next step for us to get involved. We started engaging with Key Opinion Leaders (KOLs), who immediately recognized the value of DiviTumTKa . This led to further discussions and ultimately a strategic partnership to promote blood-based biomarkers and personalized medicine.

What are the clinical needs that DiviTum TKa addresses and how are you working to integrate it into clinical routines?
DiviTumTKa addresses a crucial clinical need for effective monitoring of cancer treatments. We actively engage with oncologists and KOLs to demonstrate the assay's clinical benefit and facilitate integration into routine practice. Before the more wide-scale commercialization begins, our focus will be on winning the support of medical professionals and ensuring that DiviTum TKa becomes an accepted tool in the management of cancer.

How have the sales gone so far and what are the main driving forces for future sales?
Even though commercialization has begun, we expect the initial clinical uptake to be moderate. There is enormous support, however, from the KOLs in Sweden and we will be using that to gain momentum. The driving forces for future sales will be a combination of additional studies, target-oriented sales and marketing initiatives, as well as recommendations from oncologists.

What obstacles do you anticipate encountering before DiviTum TKa is widely used? How will you tackle those obstacles?
One of the challenges is getting DiviTum TKa included in clinical guidelines. Despite the positive clinical data, additional studies are needed in order to meet the criteria for inclusion. We are also aware of the need to navigate through the various regulations and ensure payment for the assay. But we are committed to overcoming these obstacles via strategic initiatives and continued collaboration with key stakeholders.

Do you have any other insights or initiatives you'd like to tell us about that have to do with Axlab's role in driving innovation in the area of cancer monitoring?
One of our focus areas is to address the issue of long waiting times in healthcare, especially when it comes to diagnostic imaging. By offering solutions like DiviTum TKa , we hope to relieve some of the pressure on existing resources and generate cost savings for caregivers. We are excited about the opportunities that lie ahead for us and committed to advancing the care of cancer patients through innovation and collaboration.

INTERVIEW BAHDJA BENKHEROUF, PALEX MEDICAL

BAHDJA BENKHEROUF
ONCOLOGY UNIT DIRECTOR AT PALEX MEDICAL, BIOVICA'S PARTNER IN SPAIN

With more than 15 years of experience at Palex, Bahdja Benkherouf started her career in the IVD (In Vitro Diagnostics) Unit focusing on screening for colorectal cancer. She then moved on to breast cancer and at the end of 2021, into her current role as Oncology Unit Director.

Bahdja Benkherouf is the Oncology Unit Director at Biovica's Spanish partner Palex Medical, which is highly involved in oncology and has a proven track record in bringing new innovations to the market.

Could you please tell us a little about Palex?
At Palex, we believe in the transformative power of technology in healthcare to help change lives. We focus on continuous innovation to advance diagnostics, treatment and patient monitoring by understanding the challenges faced by healthcare professionals. We closely collaborate, attentively listen and work as a team to introduce new solutions in the healthcare sector. We also know how to adapt them to the conditions here in Spain. The focus at our Oncology Unit is on precision oncology to ensure the best possible results for cancer patients.

How did you come into contact with Biovica and DiviTum TKa ?
At Palex, we are constantly engaging with technology developers who are in need of a partner to launch their solutions in various markets. With Biovica, we met each other half way. In other words, when their business development team contacted us, we were already acquainted with their technology and company, so the collaboration been very smooth.

How did the collaboration begin?
Our decision to collaborate is driven by several critical criteria that each technology must meet before we consider implementation. First of all, the technology must be mature or nearly mature, which means that it is ready for commercial launch. It must also be innovative, address a clear medical need and have the support of robust, evidence-based research. Equally important is for us to seek out partners who value Palex's contribution and are interested in establishing a long-term, strategic partnership rather than just a commercial distribution agreement.

Could you please explain the clinical need of DiviTum TKa ?
Breast cancer treatment is in need of biomarkers that are simple, cost-effective and suitable for significant therapeutic applications. DiviTumTKa meets these criteria and offers unique value when it comes to guiding the use of CDK inhibitors for the treatment of metastatic breast cancer. Although these inhibitors have revolutionized the treatment of HER2-negative, hormone receptor-positive (HR+) breast cancer, there is currently no biomarker for tailoring their use. This lack of clinicopathological criteria makes it difficult to predict which patients will benefit from CDK inhibitors and which may require other treatments. DiviTumTKa offers a cost-effective solution to this challenge, which facilitates a more tailored method of treatment.

What are you doing to ensure that oncologists implement DiviTum TKa into their clinical routines?
Our multidisciplinary teams serve as reliable advisors for caregivers and they are building relationships via innovative and transformative solutions. We have helped reduce the use of chemotherapy on the Iberian peninsula thanks to our prior involvement in precision technology and our groundbreaking introduction of a significant multigenomic platform for breast cancer. It is experience that has made us a leader in precision oncology, with the ability to offer specialists new technology that improves patient care. As a full-range partner, we help both developers and medical professionals integrate cutting-edge precision oncology technology into clinical practice.

Are there any aspects specific to the Spanish market?
To ensure the success of a new technology like DiviTum TKa , it is important to consider the specific ecosystem where the technology will be used. For Spain and other European countries, clinical benefit and cost-effectiveness must always be considered. We have created an internal structure and organization that enables us to not only be a commercial partner, but also serve as an extension of our partners in the markets where we do business.

How has clinical uptake been so far?
Right now, we are focusing our activities on the reference centers that we have identified as both innovative and early adapters. Making sure that their experience is good will help ensure and increase scalability. The feedback we have received from them thus far has been incredibly positive.

What are the most important drivers for future sales?
Critical factors for future success include evidence generation, adaptability to clinical needs and involvement of experts. In an increasingly regulated and demanding environment, it is crucial to generate robust evidence in order to establish DiviTumTKa's clinical benefit, cost-effectiveness and positive impact on local medical practice. The ability to adapt to emerging clinical requirements and expand usage to a wider group of patients is also important. Equally important is securing support from medical experts. Building up a group of prior users who can confirm and share their experiences of concrete advantages with DiviTum TKa will be a crucial driver for acceptance and integration into clinical routines.

Have you identified any obstacles?
Healthcare systems are increasingly under financial strain. They have been designed for quick introduction of pharmaceuticals, but not for diagnostic solutions (IVD). We also have to consider the workload of caregivers and lack of specialized human resources. We certainly do not want new technology to add additional strain to departments that are already overburdened (e.g. labs and primary care). From a clinical perspective, it must also continue to generate evidence in order to demonstrate the clinical benefit of DiviTum TKa and its potential cost-effectiveness, all of which must be at a level that meets or exceeds what is required for pharmaceuticals.

Is there anything else you would like to add?
We are happy to be collaborating with Biovica. We believe that DiviTum TKa is a new technology that can offer enormous support to clinics when making treatment decisions. Patients benefit from treatment that is more tailored to their needs and the financial strain on hospitals improves when there is better resource utilization of expensive medicines.

Collaborations in pharmaceutical industry increase the future potential

Biovica made progress during the financial year with its pharma collaborations. This part of the business provides support for drug development and diagnostics by offering testing services for TKa, review of study results, guidance on the timing and frequency of patient sampling aimed at optimal TKa measurements and help with interpreting the test results. In other words, we help with all the key activities associated with using TKa as a biomarker for monitoring drug effect and patient stratification thereby enhancing the CDx potential of TKa.

During the financial year, Biovica added another six pharmaceutical and biotech companies to its list of partners, (companies that have signed a master service agreement (MSA) with Biovica), bringing the total to 14 such agreements. Each one includes between one and three work orders where Biovica will offer testing services on the customer's preclinical and clinical trial samples. Besides that, Biovica has a handful of customers who are either evaluating the company's technology prior to possibly signing an MSA or are purchasing kits through their CRO labs.

Thanks to TKa's usefulness in monitoring the treatment response of patients, or lack thereof, many of Biovica's MSA customers have progressed from smaller preclinical studies involving around 50-150 samples to larger clinical studies involving around 500-1,500 samples. The sharp increase in number of signed MSAs and the size of the associated work orders is reflected in the growth of Biovica's pharma activities, which nearly doubled during the financial year.

Biovica's ability to offer high quality services and collaborations from its laboratories in both Uppsala and San Diego are of great value to the company's pharmaceutical and biotech customers. Biovica's lab in the USA received CAP accreditation in October 2023, which also serves as an important stamp of quality for these customers. Approximately 95 percent of Biovica's pharmaceutical and biotech customers currently obtain their services from the US lab. It is a CLIA-certified, CAP-accredited laboratory that offers validated (analytical and clinical) DiviTum TKa analyses. These three parameters are very important to pharmaceutical and biotech customers when they sign agreements with Biovica.

Furthermore, the rising number of Research Use Only (RUO) samples processed at Biovica's laboratories has further optimized the work flow and Biovica offers a TKa testing time that is very attractive to its pharmaceutical and biotech customers.

Positive IPRP opens the door for immune checkpoint inhibitors

Most of Biovica's pharmaceutical customers are involved in the development of antiproliferative drugs, mainly CDK4/6 inhibitors and selective estrogen receptor antagonists/modulators (SERDs/SERMs). In March 2024, Biovica received a positive IPRP (International Preliminary Report on Patentability) covering the use of TKa as a prognostic and monitoring marker outside the breast cancer space, including the market for immune checkpoint inhibitors (ICI).

The European Patent Office (EPO) concluded that all claims are indeed novel and inventive, covering "cancer" as a broadly used term and not limited to just one type of cancer. The fact that TKa technology can be used more widely as a liquid-based tool for monitoring drug efficacy in cancer treatment – not only with the CDK 4/6 inhibitor and SERM/SERD drug types – but also with checkpoint inhibitors (ICIs) will significantly increase the market potential of TKa.

Project Optimus

In 2021, the FDA launched an initiative called Project Optimus aimed at reforming and improving dose optimization. The goal is to improve drug development by focusing on minimum effective dose (MED) rather than maximum tolerated dose (MTD). Doing so will reduce the burden of side effects that patients experience.

During the financial year, there was a significant increase in the demand from pharmaceutical and biotech companies for tools and biomarkers able to identify the most effective dose for a patient and determine which patients are most likely to benefit from a specific treatment.

Biovica has noticed an increased interest in TKa thanks to its strong, clinically-proven ability to monitor the treatment response of patients. Biovica believes that TKa will play an important role in Project Optimus by providing insights into treatment response with different drug doses and helping pharmaceutical and biotech companies meet the new dosing guidelines.

CDx – attractive opportunity for developing new products

Companion Diagnostic (CDx) is a concept that has become well established in the field of oncology over the last 20 years or so. Companion Diagnostic tests help match a patient to a specific drug or therapy. It creates benefits to everyone involved, which means patients, payers, pharmaceutical companies and diagnostic companies.

As regards monitoring, there are few examples of successful CDx collaborations even though, for example, the FDA is demanding it so that treatment outcomes will improve. It thus creates a unique opportunity for Biovica to develop these types of collaborations, particularly since the company already has sales to some of the largest pharmaceutical companies in that area, as well as employees with unique experience in developing these types of products.

DiviTum TKa has strong clinical evidence and proven clinical benefit

Favorable results from clinical studies are a prerequisite for successful launch of a diagnostic product. Biovica's strategy is to generate strong results from studies showing DiviTum TKa 's accuracy and clinical usefulness, along with collaborating with researchers in order to quickly publish the results in prestigious scientific journals. It generates demand, as well as the support for pricing and inclusion in reimbursement systems. Furthermore, Biovica's collaboration with many world-leading cancer institutes and oncologists is increasing awareness and demand for the product.

Biovica's goal is to facilitate better treatment decisions and enable doctors to more easily determine when a treatment is still effective and when it should be replaced by a new one. Another aim is to show that it is possible to cut down on the use of other diagnostic testing when DiviTum TKa is used.

The most important conference for Biovica is San Antonio Breast Cancer Symposium (SABCS), which is the world's largest breast cancer symposium. It was most recently held in December 2023 and this was the eighth year in a row that data on DiviTum TKa was accepted by SABCS and three posters based on studies with DiviTum TKa were presented. These posters reinforce how the DiviTum TKa test has value as a response indicator and predictor for hormone receptor-positive (HR+) patients with metastatic breast cancer (MBC) treated with CDK4/6 inhibitors, the most prescribed drug class for this patient population.

More about the three posters presented at SABCS

1.

"Serum thymidine kinase activity as a "real time" biomarker of tumor response to CDK4/6 inhibition in HR+ metastatic breast cancer" is based on the TK IMPACT study at Washington University. It is a prospective study to evaluate how real-time measurements of TKa activity impact a physician's decision about altering the use and/or timing of other routine monitoring options. The study highlights several interesting patient cases where DiviTum TKa demonstrated its ability to improve monitoring compared to other standard monitoring tools.

2.

"Genomic and PAM50 correlates of serum thymidine kinase activity (sTKa) in patients (pts) with metastatic breast cancer (MBC) treated with palbociclib (P) and Fulvestrant (F) in the PYTHIA trial" is a sub-analysis from the PYTHIA study for which topline results have already been presented. The study looked at the correlation between TKa levels, intrinsic breast cancer subtypes, and the presence of the three most common genomic tumor mutations (p53, PIK3CA, and ESR1). The data showed that baseline TKa levels were higher in luminal B and HER2-enriched intrinsic subtypes and that the DiviTumTKa test was more strongly predictive of progression-free survival than the presence of mutations in p53, PIK3CA, or ESR1 genes.

3.

"Use of DiviTum-TKa test as a biomarker assay for CDK4/6 inhibitor medication compliance and drug-drug interaction assessment in ER/PR positive metastatic breast cancer" is based on the ongoing prospective clinical trial that was started at Yale in August 2023 to use the DiviTumTKa test to identify suboptimal TKa responses caused by medication compliance or drug-drug interaction issues in patients taking a CDK4/6 inhibitor.

"

All three posters are very interesting, but seeing DiviTumTKa performing better than other standard monitoring tools in several patient case studies from the TK IMPACT trial of course makes me extra proud.

ANDERS RYLANDER
CEO OF BIOVICA

Biovica at ASCO – supports clinical benefit

A poster displaying the DiviTum TKa results from the SWOG S0226 trial was presented at the world's largest cancer symposium, ASCO, on 4 June 2023. Investigators involved in the trial concluded, among other things, that DiviTum TKa values at the start of treatment are very prognostic. Because it compared DiviTum TKa with one of the assays routinely being used today, CA 15-3, Biovica feels that the trial results provide important support for commercialization of the assay.

Here are the investigators' conclusions[3]:

- DiviTum TKa values at the start of treatment are very prognostic for patients with Hr-positive metastatic breast cancer receiving first line systematic endocrine treatment (low TKa at the start of treatment = superior prognosis)
- CA 15-3 at the start of treatment is not prognostic at the start of treatment and only becomes prognostic after three treatment cycles
- High baseline TKa CA 15-3 values are less prognostic
- DiviTum TKa and CA 15-3 are complementary biomarkers, which offer a more complete understanding of disease status.

3. Ref: E Cobain et al, J Clin Oncol 41, 2023 (suppl 16; abstr 1076)

ONGOING STUDIES

DiviTum TKa is being used in several ongoing national and international retrospective, prospective and interventional clinical studies. Each has been carefully chosen to both add and strengthen data that can support the use of DiviTum TKa for monitoring cancer treatment and as an effective tool for evaluating treatment effect. DiviTum TKa is currently included in seven published ongoing studies on metastatic breast cancer and one study on locally advanced breast cancer. DiviTum TKa is also included in several other studies where it has not yet been made public that DiviTum TKa is being used.

Biovica will also continue its research collaborations with Johns Hopkins, Mayo Clinic, Christie Hospital, Karolinska Institutet, Prato Hospital and many others to add to the growing body of strong data that supports clinical use of DiviTum TKa. Through its Scientific Advisory Board (SAB), Biovica also collaborates with 12 of the leading breast cancer specialists in the USA in order to share and discuss current DiviTum TKa data. The feedback from this has been extremely positive, resulting in new ideas about potential new research collaborations for future studies.

ONGOING STUDIES IN BRIEF

Study	Number of patients	Indication	Focus of the study
Johns Hopkins	42	Metastatic breast cancer	Identification of resistance development
TIRESIAS	150	Metastatic breast cancer	Early identification of resistance
PDM-MBC	100	Metastatic breast cancer	Monitoring and less imaging
TK IMPACT	40	Metastatic breast cancer	Evaluation of clinical usefulness
PREDIX	180	Locally advanced cancer	Evaluation of clinical usefulness
Yale	120	Metastatic breast cancer	Correlation between DiviTum TKa levels and the effects of lower dosage
BettER	50	Metastatic breast cancer	The impact of early therapeutic switching based on insights using DiviTum TKa
Mayo Clinic	100	Metastatic breast cancer	Observational trial
TOTAL	**782**		

PUBLISHED STUDIES

Type of cancer	Number of patients	Number of studies
Breast	3,039	14
Gastro	713	4
Blood	440	4
Lung	302	3
Malignant melanoma	86	2
Other	457	3
TOTAL	**5,037**	**30**

For many years, Biovica has been collaborating with world-leading academic institutions and Key Opinion Leaders (KOLs). These collaborations have produced strong evidence supporting the use of DiviTum TKa as a clinical biomarker for measuring treatment response to CDK4/6 inhibitors. Commercialization of the assay pended on this important evidence. Thus far, more than 5,000 patients have participated in more than 30 studies with DiviTum TKa. Validation of the assay occurred through these studies and Biovica continues to support studies with DiviTum TKa to further validate its usefulness, which is one of the factors that will serve as the basis for reimbursement and inclusion in guidelines.

“

We are excited to offer patients with ER+ HER2- advanced breast cancer the opportunity to incorporate TK testing with the goal of further tailoring treatment, reducing unnecessary toxicity and improving patient outcomes

KATHERINE CLIFTON
M.D., BREAST MEDICAL ONCOLOGIST AND THE LEAD INVESTIGATOR OF THE TRIAL AT WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUIS.

CDK 4/6-inhibitors

Cyclin-dependent kinases (CDKs) 4 and 6 play an important role in controlling the cell cycle. CDK4/6 inhibitors "shut down" these kinases and thereby slow down the cell cycle, which inhibits the growth of cancer cells. Hormone receptor-positive breast cancer cells are sensitive to the anti-proliferative effects of CDK4/6 inhibitors, particularly in combination with endocrine therapy.

782

PATIENTS PARTICIPATING IN ONGOING STUDIES WITH DiviTumTKa

8

PUBLISHED ONGOING STUDIES

>5,000

PATIENTS HAVE PARTICIPATED IN PUBLISHED STUDIES WITH DiviTumTKa

ONGOING STUDIES WHERE DiviTumTKa IS BEING USED

- **Johns Hopkins |** Together with one of the leading universities in the USA, Johns Hopkins University, Biovica is conducting a study involving 42 patients to document biomarkers and measure the development of resistance to CDK4/6 inhibitors. The objective of the study is to find markers to identify early development of resistance of today's standard treatment in combination with Ibrance® (palbociclib, Pfizer). By early identification of women who are not responding to treatment, these patients can be offered other therapies and the opportunity for more effective treatment and better outcome.

- **TIRESIAS |** In January 2021, DiviTumTKa was selected to be included in the prospective clinical study, TIRESIAS, with the aim of investigating if DiviTumTKa can be used to identify early resistance to treatment. TIRESIAS is a multi-center study that will collect samples from 150 patients with hormone receptor-positive metastatic breast cancer who receive the first-line standard treatment: a CDK4/6 inhibitor and an aromatase inhibitor. The aim is to demonstrate that DiviTumTKa can predict progression free survival and clinical benefit from samples taken as early as two weeks into treatment.

- **PDM-MBC** *(Personalized Disease Monitoring in Metastatic Beast Cancer)* **|** DiviTumTKa was selected in November 2020 for inclusion in a new prospective UK breast cancer study of 100 women with hormone receptor-positive metastatic breast cancer. The study, which is being led by researchers at Christie Hospital in Manchester, is investigating whether DiviTumTKa can be used for disease monitoring during treatment with a CDK4/6 inhibitor and aromatase inhibitor. The hypothesis is that routine imaging can be delayed until predefined levels of biomarker progression is detected.

- **TK IMPACT |** In November 2021, Biovica announced that it will be supporting the TK IMPACT study, which is an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of DiviTumTKa for monitoring patients with hormone receptor-positive (HR+) metastatic breast cancer receiving CDK4/6 inhibitor treatment. The study is very important to Biovica since it is the first study where doctors who are treating patients will regularly receive TKa data, which will enable them to make treatment decisions based on TKa levels. Data from this study will be crucial for defining the clinical usability of DiviTum TKa .

- **PREDIX study |** at Karolinska University Hospital, DiviTumTKa is being used to identify disease progression and response to CDK4/6i treatment for 180 patients with locally advanced breast cancer.

- **Yale |** This prospective clinical trial was initiated in August 2023. Among others, it will investigate the correlation between DiviTum TKa levels and the effects of medication dose reductions in the care of ER/PR-positive HER2-negative metastatic breast cancer patients who are receiving first-line therapy with a CDK4/6 inhibitor in combination with endocrine therapy. The targeted number of participants is 120 patients, and the study duration is expected to be 12 to 18 months.

- **BettER |** In March 2024, Biovica announced that a clinical interventional trial had been launched at Washington University School of Medicine i St. Louis. The study is aimed at evaluating whether patients with HR+ HER2- metastatic or inoperable breast cancer benefit from DiviTum TKa. The study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights using DiviTum TKa. Patients demonstrating insufficient TKa suppression will be recommended for an alternative therapy, potentially enhancing treatment outcomes. There will be 50 patients enrolled in the study.

- **Observational trial at Mayo Clinic |** In April 2024, Biovica announced the start of an observational trial at Mayo Clinic in Florida. It will evaluate DiviTum TKa 's capacity as a predictive blood-based biomarker that can significantly impact treatment response, selection strategies, assessment of tumor aggressiveness, and patient survival rates. Over a period of two years, it will investigate 100 patients with hormone receptor-positive (HR+) metastatic breast cancer undergoing standard of care therapies – either CDK4/6 inhibitors combined with endocrine therapy (ET) or ET monotherapy – providing up to 27 serial samples per patient throughout that time.

Strong protection that goes beyond strong patents

The patents for DiviTum TKa expire in 2026 and 2031 for the two different patent families, which cover two different technology platforms, ELISA and PCR. Both platforms measure TK and the correlation between them is high.

During the development of DiviTum TKa , Biovica accumulated considerable know-how that would make it difficult for others to copy it. Even after the patents expire, Biovica expects that it will retain strong protection since neither the manufacturing process nor compilation of the test is disclosed in the patent specification. The risk that Biovica's technology is copied is further lowered by the fact that Biovica does not share this type of knowledge with any production partners.

In many countries, comprehensive clinical documentation is also required in order to receive regulatory clearance for commercialization of a diagnostic test. Demonstrating that a copied product works as well as DiviTum TKa would be a difficult and costly task.

Biovica also received a positive International Preliminary Report on Patentability (IPRP) immunotherapies. The patent application covers the use of TKa as a prognostic and monitoring marker for immunotherapies (immune checkpoint inhibitor, ICI), which expands the market potential for the DiviTum TKa technology by four to six times.

The decision was issued by the EPO (European Patent Office), which is also the International Examining Authority. This eliminates the need for submitting an international patent in Europe. The EPO concluded that all claims are indeed novel and inventive, covering "cancer" as a broadly used term and not limited to just one type of cancer. This facilitates a quick process for patent issuance in Europe.

Outside Europe, other patent authorities will decide on the extent to which they will consider this IPRP. The IPRP will now be sent by the International Bureau of the World Intellectual Property Organization to the various designated offices for their consideration during the national phases.

49

AT PRESENT, BIOVICA HAS PATENTS IN 49 COUNTRIES



SUSTAINABILITY EFFORTS

Biovica's sustainability efforts are based on the 17 UN Sustainable Development Goals. In total, Biovica has focused on five of these goals, which represent the areas where Biovica can contribute most and make a difference.

By offering DiviTumTKa, Biovica helps improve the health of women suffering from metastatic breast cancer. The vision is to improve the quality of life for cancer patients.

Biovica believes that all people have equal worth, regardless of, for example, their gender or ethnicity. These values govern both how the company recruits and interacts with employees and stakeholders alike.

As an employer, Biovica strives to provide a good work environment, with opportunities for development and market-based terms.

Biovica's innovative technology will help lower the reliance on other technologies that have a negative impact on both health and the environment. By replacing such technologies with monitoring of cancer treatments, Biovica helps reduce travel for patients, along with their exposure to radiation, which is beneficial to both health and the environment.

Biovica strives to minimize negative impact on the environment. Biovica does this by packaging efficiently and using as much environmentally-friendly and recyclable material as possible. Besides that, efficient packaging helps lower the environmental impact of transports. Furthermore, Biovica considers the environmental aspects of employee business trips. Unnecessary travel should be avoided and priority given to more environmentally friendly travel options whenever possible.

Sustainability – new initiatives started in FY23/24

Biovica's sustainability work is closely associated with the company's vision of improving the quality of life for cancer patients in a way that also respects our planet. The core of the business, and the company's most important contribution to sustainable development, is to make safer and more effective diagnostics available to cancer patients, with the aim of creating long-term value for shareholders while contributing positively to society and minimizing negative effects on the environment. Integrating sustainability into our business strategy is critical to maintaining our position as a reputable and competitive company in today's business.

Core values

Biovica actively strives to continually improve its company culture. Biovica's core values clearly capture the principles that provide the foundation for our organization and its culture along with how the company makes decisions and how we interact with each other, our customers, owners, partners and other stakeholders.

Collaboration – We work as a team, supporting each other to become successful.

Innovation – We use technology to create innovative, sustainable solutions for carrying out our mission.

Appreciation – We behave ethically and responsibly in order to build confidence.

Dedicated employees are the key to success

Employee commitment, initiative and motivation to perform contribute to Biovica's success. The company culture fosters dedication and entrepreneurial spirit. We also have a decentralized organizational structure where all employees contribute to the end results. Biovica's employees are aligned in pursuing the vision of improving the quality of life for cancer patients. All employees at Biovica have the same mission, namely, to bring about a change in how cancer care is monitored by offering innovative biomarker assays.

Commitment and clarity are values that permeate the entire organization. At Biovica, we want every employee to feel proud of their contribution to the company's success. Biovica strives for equality, sustainability and to provide a healthy work environment where every employee is able to perform, develop and thrive. Future growth and success require that Biovica continually works with the brand and strengthening the company's reputation as an attractive employer.

Biovica has operations in two countries and most employees are employed in Sweden. At the end of the financial year, Biovica had 32 employees, 7 in the USA and 25 in Sweden. Of the total number of employees, 55 percent are female and 45 percent are male. Biovica strives to achieve and maintain an even gender balance at the company.

Over the last few years, employee turnover and absence due to illness have been at low, sustainable levels at Biovica. The results from our employee satisfaction surveys also indicate that our employees enjoy their work.

An attractive workplace

With that in mind, Biovica is focusing on the following areas: work environment, skills development, sustainability and self-leadership.

Biovica expects a lot from its employees and they, in turn, can expect a lot from Biovica. Over the last few years, Biovica has invested in benefits and incentives that provide employees with more security and higher quality of life. Biovica's employees have salary options for making higher pension provisions, subsidized fitness memberships, wellness programs and fun team-building activities.

PHARMA COLLABORATION

Biovica's pharma collaborations have been a driving force for its sustainability efforts. In the coming years, sustainability investments and reporting will be integrated into business terms and conditions, stakeholder requirements, customer expectations and government regulations.

Biovica has selected three sustainability initiatives over the short term (next 6-12 months) and one over the long term (by the end of 2030).

Short-term initiatives

1. Valid ESG rating

Biovica recently set up a project team tasked with creating an ESG report for Biovica that can be submitted for evaluation by a leading global provider of business sustainability ratings, such as Ecovadis. Our goal is to have the report ready by the end of the 2024 calendar year.

2. Report environmental measures to CDP

CDP (Carbon Disclosure Project) was set up to develop a standardized environmental reporting model that is aligned with the world's most relevant frameworks and standards. Completing the CDP questionnaire will help Biovica identify its environmental risk management practices and opportunities for limiting its environmental impact, as well as generating environmental performance information for investors, customers and the market. Our goal is to begin our annual reporting no later than the second or third quarter of the 2025 calendar year.

3. Alignment with the Science Based Targets initiative (SBTi)

The Science Based Targets Initiative promotes best practice in emissions reductions and net-zero targets in line with climate science. SBTi guides companies on how much and how quickly they need to reduce their greenhouse gas emissions in order to meet the Paris Agreement's 2015 global warming targets. SBTi is a non-profit organization with a team of experts that can provide companies with an independent assessment and validation of their emission reduction targets. More than 5,700 companies around the world have joined SBTi. Biovica's goal is to align itself with SBTi by following its target setting process by the end of 2024. Over the next 24 months, Biovica will develop an emission reduction target in line with the SBTi criteria and submit it to the SBTi for official validation.

Long-term initiative:

Biovica will reduce the use of non-renewable and non-recyclable resources and greenhouse gas emissions from its own operations and supply chain, and by the end of 2030 will have reduced its greenhouse gas emissions by 50 percent.

Biovica shares

Biovica's shares became listed on Nasdaq First North Growth Market Stockholm on 29 March 2017 and are included in the First North All-Share SEK index and the First North Health Care PI index. Since 4 March 2019, the company has been listed on Nasdaq First North Premier Growth Market. Since 4 March 2019, the company has been listed on Nasdaq First North Premier.

Biovica has two share classes: Class A shares (3 votes each) and Class B shares (1 vote each). Registered share capital is SEK 5,603,704 allocated across 84,055,560 shares of which 6,271,293 are Class A shares and 77,784,267 are Class B shares. The quotient value is SEK 0.07 per share.

Nasdaq First North and Certified Adviser

First North Growth Market is an alternative marketplace for Nordic growth companies that is designed primarily for small and medium-sized companies. It does not have the same legal status as a regulated market and the regulations are somewhat less extensive than those that apply to the stock exchange's larger marketplaces.

All companies whose shares are traded on First North Growth Market have a Certified Adviser who monitors that the company complies with First North Growth Market's regulations for providing information to the market and investors.

FNCA Sweden AB is the appointed Certified Adviser.
Phone: +46 8 528 00 399,
E-mail: info@fnca.se

TRADING INFORMATION

Ticker symbol on Nasdaq First North Stockholm: BIOVIC B
ISIN code: SE0008613731
LEI code: 549300VADE1VRR555N78
The shares are registered by Euroclear Sweden AB.

SHARE PRICE GROWTH

During the financial year, the price of the Biovica share fell 77 percent, compared to OMX Stockholm PI, which rose by 12 percent during that same period. The highest closing price was SEK 9.44 on 3 August and the lowest closing price was SEK 1.59 on 30 April.
On 30 April 2024, the listed price for shares in Biovica was SEK 1.59, corresponding to market capitalization of SEK 134 million.



THE TEN LARGEST OWNERS AS OF 30 APRIL 2024

Name	Number of class	Share of capital, %	Share of votes, %
Anders Rylander	9,030,124	10.74%	16.88%
Avanza Pension	5,826,909	6.93%	6.03%
Mattias Sesemann	2,350,000	2.80%	2.43%
Gunnar Rylander Estate	2,085,225	2.48%	4.09%
Handelsbanken Liv Försäkring AB	2,043,318	2.43%	2.12%
Mats Danielsson	1,750,394	2.08%	1.81%
Nordnet Pensionsförsäkring	1,725,668	2.05%	1.79%
Gunvald Berger	1,303,263	1.55%	1.35%
Formue Nord A/S	1,207,247	1.44%	1.25%
Lars Holmqvist	1,037,417	1.23%	1.07%
	28,359,565	**33.7%**	**38.8%**
Other shareholders	55,695,995	66.3%	61.2%
Total number of shares	**84,055,560**	**100%**	**100%**

Source: Holdings

SHARE-RELATED INCENTIVE PROGRAMS

Biovica has seven ongoing incentive programs. The table below provides an overview of the content of each program.

Program	To	Class B shares	Subscription price	Option price	Subscription period	Share capital increase	Number of class B shares
TO8	employees	241,648	70.35	2.61	25 March 2023 – 25 August 2024	16,110	241,648
PO9	employees	134,825	70.35	-	25 March 2023 – 25 August 2024	8,998	134,825
TO10	Board of Directors	124,454	70.35	3.94	1 August 2025 – 30 September 2025	8,297	124,454
23/26:1	employees	240,000	10.13	-	1 June – 30 September 2026	16,000	240,000
23/26:2	employees	56,000	10.12	-	1 July 2023 – 15 September 2026	3,733	56,000
23/26:3	employees	358,000	7.49-12.62	-	1 October – 1 November 2026	23,867	358,000
23/26:4	Board of Directors	195,000	7.49-12.62	-	1 October – 1 November 2026	13,000	195,000
23/26:5	employees	155,250	12.66	-	1 October – 1 November 2026	10,350	155,250
23/26:6	employees	51,750	11.10	-	15 September – 1 November 2026	1,333	51,750
		1,556,927				**103,795**	**1,556,927**

GROWTH OF SHARE CAPITAL OVER TIME

The table below shows the historical growth of Biovica's share capital 2008 until the present time.

		Number of class				
Registration date	Event	Change	Total	Share capital (SEK)	Total	Quotient value
2023-12-21	New share issue	38,314,166	84,055,560	2,554,278.00	5,603,704.00	0.07
2022-12-15	New share issue	17,153,022	45,741,394	1,143,534.79	3,049,426.27	0.07
2022-08-23	Share subscription due to warrants	60,000	28,588,372	4,000.00	1,905,891.44	0.07
2022-07-15	Share subscription due to warrants	20,000	28,528,372	1,333.33	1,901,891.45	0.07
2022-06-29	Share subscription due to warrants	20,000	28,508,372	1,333.33	1,900,558.11	0.07
2022-04-14	Share subscription due to warrants	20,000	28,488,372	1,333.33	1,899,224.78	0.07
2021-10-01	Share subscription due to warrants	10,000	28,468,372	666.67	1,897,891.45	0.07
2021-09-22	Share subscription due to warrants	20,000	28,458,372	1,333.33	1,897,224.78	0.07
2021-08-18	Share subscription due to warrants	20,000	28,438,372	1,333.33	1,895,891.45	0.07
2021-01-28	Share subscription due to warrants	145,000	28,418,372	9,666.67	1,894,558.11	0.07
2020-08-25	New share issue	4,700,000	28,273,372	313,333.33	1,884,891.45	0.07
2019-05-07	New share issue	6,000,000	23,573,372	400,000.00	1,571,558.12	0.07
2017-04-06	New share issue	4,800,000	17,573,372	319,999.99	1,171,558.12	0.07
2016-07-29	New share issue	2,300,000	12,773,372	153,333.33	851,558.12	0.07
2016-07-29	New share issue	690,000	10,473,372	46,000.00	698,224.79	0.07
2016-07-29	New share issue	465,875	9,783,372	31,058.33	652,224.79	0.07
2016-05-24	New share issue	931,747	9,317,497	62,116.47	621,166.46	0.07
2016-04-28	Split 1:15	7,826,700	8,385,750	-	559,050.00	0.07
2016-04-19	New share issue	6,346	559,050	6,346.00	559,050.00	1.00
2016-01-12	New share issue	50,625	552,704	50,625.00	552,704.00	1.00
2015-06-08	New share issue	61,150	502,079	61,150.00	502,079.00	1.00
2015-05-15	Exchange of convertibles	54,080	440,929	54,080.00	440,929.00	1.00
2015-05-15	Decrease in share capital	-12,500	386,849	-12,500.00	386,849.00	1.00
2014-08-14	New share issue	82,893	399,349	82,893.00	399,349.00	1.00
2014-07-07	Decrease in share capital	-12,500	316,456	-12,500.00	316,456.00	1.00
2013-09-25	New share issue	45,987	328,956	45,987.00	328,956.00	1.00
2012-07-16	Decrease in share capital	-	282,969	-25,000.00	282,969.00	1.00
2012-07-16	New share issue	25,000	282,969	25,000.00	307,969.00	1.09
2012-07-05	Bonus issue	-	257,969	25,000.00	282,969.00	1.10
2012-07-05	Decrease in share capital	-25,000	257,969	-25,000.00	257,969.00	1.00
2011-06-01	New share issue	3,906	282,969	3,906.00	282,969.00	1.00
2011-06-01	New share issue	39,063	279,063	39,063.00	279,063.00	1.00
2010-06-09	New share issue	50,000	240,000	50,000.00	240,000.00	1.00
2009-11-06	New share issue	30,000	190,000	30,000.00	190,000.00	1.00
2009-02-24	New share issue	60,000	160,000	60,000.00	160,000.00	1.00
2009-02-24	Split 1:100	99,000	100,000	-	100,000.00	1.00
2008-12-29	New formation	1,000	1,000	100,000.00	100,000.00	100.00

Corporate governance report

STRUCTURE FOR CORPORATE GOVERNANCE

The external governance tools consist of: the Swedish Companies Act, the Annual Accounts Act, Nasdaq Stockholm's regulations for issuers and the Swedish Corporate Governance Code.

The internal governance tools consist of: the Articles of Incorporation that have been adopted by the AGM, internal instructions and guidelines. Examples of the internal instructions and guidelines are the Board's rules of procedure and instructions to the CEO.



Good corporate governance is about ensuring that companies are managed in a way that is as efficient for shareholders as possible. Corporate governance at Biovica is based on Swedish Law, primarily the Swedish Companies Act, Annual Accounts Act and the Swedish Corporate Governance Code (the Code). Biovica stock is traded on Nasdaq First North Premier Growth Market and accordingly, Biovica complies with the applicable legislation, Nasdaq First North Nordic's rules and regulations and statements issued by the Swedish Securities Council on good practice in the Swedish securities market. During the 2023/2024 financial year, Biovica did not have any departures from the Code.

AGM

The AGM is Biovica's highest decision-making body. The Annual General Meeting is held each year within six months of the end of the financial year. The Annual General Meeting shall be held within six months after the end of the previous financial year in order to, among other things, present and adopt the statutory financial statements and reports, appropriate earnings and resolve to discharge the members of the Board from liability. All shareholders registered in the shareholders' register who have announced their intent to participate by the date specified in notice of the AGM are entitled to participate in the meeting and exercise their voting rights. A shareholder who would like to have a particular matter dealt with at the AGM must, well in advance of the AGM, submit their request to the AGM, using the address published on the company's website. The Board of Directors may also, beyond the AGM, summon shareholders to extraordinary general meetings. Biovica's Articles of Incorporation do not contain any limitations on how many votes each shareholder may exercises at the AGM.

Resolutions at the extraordinary general meeting in May 2023 included:

- Stock options for staff in the USA (23/26:1) of 168,000 options.
- Performance shares for staff in the USA (23/26:2) of 56,000 shares

Resolutions at the 2023 AGM included:

- Adoption of the Parent Company income statement and balance sheet, as well as the consolidated income statement and balance sheet
- Profit or loss distribution in accordance with the Board's proposal, i.e. carried forward.
- Discharge of liability for Board members and CEO for the 2022/2023 financial year.
- The following Board members were reelected:
  Lars Holmqvist, Maria Holmlund, Marie-Louise Fjällskog, Annika Carlsson Berg, Ulf Jungnelius, Anders Rylander and Jesper Söderqvist. Lars Holmqvist was elected as the Chairman of the Board.
- Grant Thornton Sweden AB was re-elected as the company's auditor. Authorized Public Accountant, Stéphanie Ljungberg, will continue as the auditor-in-charge.
- Remuneration to the Board and committees. Remuneration to Board members (SEK 200,000) and Chairman of the Board (SEK 450,000) were left unchanged compared to the previous year. Remuneration to Committee Chairman was increased to SEK 75,000 (50,000) and for Committee Members, it was increased to SEK 37,500 (25,000).
- Resolution on granting the Board of Directors the authority to issue new shares for a maximum amount equal to 20 % of the current number of shares.
- Share savings program (23/26:3) for employees for a maximum of 358,000 shares
- Share savings program (23/26:4) for Board of Directors for a maximum of 195,000 shares
- Stock options for staff in the USA (23/26:5) of 155,250 options.
- Performance shares for staff in the USA (23/26:6) of 51,750 shares

Resolutions at the extraordinary general meeting in November 2023 included:

- Amendment to the limits on share capital specified in the Articles of Association. The previous limits of a

minimum of SEK 1,800,000 and a maximum of SEK 7,200,000 were changed to a minimum of SEK 3,000,000 and a maximum of 12,000,000. Limits on the number of shares have also been amended. The previous limits were a minimum of 27,000,000 shares and a maximum of 108,000,000 shares, which has been changed to a minimum of 45,000,000 shares and a maximum of 180,000,000 shares.

- The rights issue for a maximum of 45,741,388 class B shares and a maximum of 20,791,540 warrants of series TO3B B. The total increase of the Company's share capital can amount to a maximum of SEK 3,049,425.87. The subscription price for the B shares is SEK 2.61 per share, TO3B was offered free of charge to those who participate in the rights issue. More information is available in the prospectus, published on the company's website.

Major shareholder

Anders Rylander is Biovica's largest shareholder with 10.74 % of the capital and 16.88% of the votes.

Nomination Committee

The Nomination Committee is responsible for submitting proposals on who should serve as chairman for general meetings of shareholders, candidates for Board members, including the Chairman of the Board, fees and other remuneration to each Board member, along with remuneration for committee work, as well as the election of, and remuneration to, external auditors.

For the period up until the 2024 AGM, the Nomination Committee consists of: Anna Rylander Eklund, representing the Rylander family and companies; Mats Danielsson representing himself and Innovicum AB; Lars Holmqvist, Chairman of the Board for Biovica.

No remuneration is paid to the members of the Nomination Committee. The Nomination Committee is entitled to request compensation from the company for reasonable costs that are necessary for the committee to carry out its assigned tasks. The mandate period for the Nomination Committee extends until a new Nomination Committee is announced. In conjunction with the Nomination Committee's work and for the purpose of own improvement efforts, the Board of Directors conducts an evaluation each year of its work and efficiency. The results of that evaluation are distributed to the Nomination Committee.

Composition of the Board of Directors

Biovica's Articles of Incorporation stipulate that the company must have at least three Board members and at most ten Board members. At the 2023 AGM, a total of seven Board members were appointed: three female and four male. Lars Holmqvist, Marie-Louise Fjällskog, Maria Holmlund, Annika Carlsson Berg, Ulf Jungnelius, Anders Rylander and Jesper Söderqvist. Lars Holmqvist was elected as the new Chairman of the Board. The CEO is always a member of the Board of Directors and is always present at Board meetings. Anders Morén, CFO at Biovica serves as secretary for the Board of Directors.

All Board members (except for Anders Rylander) are independent in relation to the Company, its management and major shareholders. Biovica is thus in compliance with the requirements issued by Nasdaq Stockholm and with the Code as regards the independence of Board members.

The work done by the Board and Board evaluation

The Board has the ultimate responsibility for directing the company's operations between the Annual General Meetings. The Board makes decisions on issues relating to the company's strategic direction, financing, major investments, acquisitions, divestments, organizational issues, incentive principles and important policies. The work done by the Board is regulated by, among others, the Swedish Companies Act, the Articles of Incorporation, the rules of procedure that the Board has adopted and the Board's instructions to the CEO. The rules of procedure clarify each Board member's responsibilities, in particular the Chairman's, as well as allocation of responsibilities between the Board of Directors and CEO along with the CEO's authorities. Those authorities have also been clarified in more detail in the instructions to the CEO. The rules of procedure also state, at an overall level, the subject areas that the Board of Directors shall cover and work with during the year, along with how time should be allocated to the various components of their work.

The Board reviewed its rules of procedure during 2023, along with instructions to the CEO and reporting instructions. It also evaluated the work done by the CEO. During the

BOARD MEMBERS AND THEIR INDEPENDENCE

Name	Position	Elected	Independent in relation to		Attendance at		
			the company and Group management	major shareholder	Board meetings	Audit committee	Remuneration committee
Lars Holmqvist	Chairman	2019	Yes	Yes	20/23	4/5	
Annika Carlsson Berg	Board member	2021	Yes	Yes	23/23		
Marie-Louise Fjällskog	Board member	2020	Yes	Yes	22/23		
Maria Holmlund	Board member	2016	Yes	Yes	23/23		11/11
Ulf Jungnelius[3]	Board member	2014	Yes	Yes	20/23		7/11
Henrik Oswald[1]	Board member	2019	Yes	Yes	6/23	2/5	
Jesper Söderqvist[2]	Board member	2013	Yes	Yes	23/23	3/5	4/11
Anders Rylander	Board member, CEO	2010	No	No	23/23		

1 Henrik Oswald resigned from the Board and as Chairman of the Audit Committee on 5 September 2023.
2. Jesper Söderqvist resigned as a member of the Remuneration Committee on 5 September 2023 and took over as Chairman of the Audit Committee at the same time.
3. Ulf Jungnelius became a member of the Remuneration Committee on 5 September 2023.

BOARD CALENDAR

Q1 MAY–JULY	Q2 AUGUST–OCTOBER	Q3 NOVEMBER–JANUARY	Q4 FEBRUARY–APRIL
• Board report/ CEO evaluation	• Strategy meeting • Annual General Meeting (AGM) • Meeting following election	• Policies	• Budget
• Year-end report • Annual report	• Annual General Meeting (AGM) • Q1 Interim report	• Q2 Interim report	• Q3 Interim report

year, the Board has had two committees: a Remuneration Committee consisting of Maria Holmlund, Chair, and Ulf Jungnelius; and an Audit Committee consisting of Jesper Söderqvist, Chair, and Lars Holmqvist. During the 2023/2024 financial year, the Board held 23 meetings where the minutes were taken.

Responsibilities of the Remuneration Committee

The Remuneration Committee is responsible for preparing matters and/or materials for decisions having to do with the following:

- Providing the Board with proposals on remuneration guidelines and other employment terms for the CEO and other senior executives (in accordance with the rules stipulated in the Swedish Companies Act). This occurs at the first ordinary Board meeting of the financial year. This includes policies on such things as salary, benefits and other employment terms for Biovica's senior executives. Examples are policies on bonus and incentive programs for the short and long term, pensions, basic salary and other employment terms.
- The Committee also makes a proposal for the CEO's salary and other benefits.

Responsibilities of the Audit Committee

The Audit Committee is responsible for monitoring corporate governance issues and how they are applied. It reviews the company's risk management routines, as well as its management and control of the financial reporting.

By maintaining a continuous dialog with the company's auditors and the accounting/finance function, the Committee shall ensure that external auditors fulfill the stipulated requirements and that there are relevant policies and governing documents in place. They also discuss with auditors the scope and focus of audit work.

Each year, the Audit Committee updates itself on the audit plan. The Audit Committee evaluates the audit work and approves any additional services that the company has engaged from the external auditors. The Committee also assists the Nomination Committee by making a proposal for the company's selected auditor, along with the fees for that work.

The Chair of the Audit Committee is responsible for keeping the entire Board continuously informed about the Committee's work and, as needed, referring any matters to the Board for a decision.

Although the Audit Committee is able to have in-depth discussions with the company's auditors, this does not replace the meetings that the auditors otherwise have with the entire Board of Directors. Such meetings take place at least once per year, typically in conjunction with the annual report.

CEO and Group management

The CEO is responsible for the ongoing administration and running of the company's business. Allocation of work between the Board and the CEO is detailed in the company's rules of procedure for the Board and instructions to the CEO. The CEO keeps the Board continuously informed about the company's operations, performance and financial position through, among others, monthly reports. The CEO is also responsible for preparing reports and compiling information for Board meetings, along with presenting that information at Board meetings.

Anders Rylander is President and CEO and leads the company's operations together with Anders Morén, CFO, Hanna Ritzén, COO, Hector Tamburini, Head of US, Helle Fisker, VP Commercial and Marketing and Henrik Winther, SVP Business Development.

Remuneration and employment terms

Board of Directors

At the AGM on 5 September 2023, it was resolved that a fee of SEK 200,000 would be paid to each member of the Board who is not an employee of the company and that the fee paid to the Chairman of the Board would be SEK 450,000. An additional SEK 75,000 shall be paid to the Chairman of each committee and SEK 37,500 to each committee member. For the 2022/2023 financial year, remuneration to the Board of Directors totaled SEK 1,675,000.

CEO and Group management

Biovica shall offer a market-competitive total compensation package such that it is possible to recruit and retain talent for its executive management team. Compensation shall consist of fixed salary, performance-based remuneration, share savings programs, pension and other remuneration. Together, it comprises an individual's total compensation package.

Fixed salary, which is reviewed each year, shall reflect the individual's areas of responsibility and experience. Performance-based remuneration is based on the individual achieving certain qualitative and quantitative targets. For senior executives, the variable portion of compensation may not exceed 50 percent of fixed salary.

The Board of Directors decides on the remuneration policy for the CEO and Group management team. The policy in place as of the date of this annual report has been designed in accordance with the guidelines for remuneration to the CEO and Group management that were adopted

by the AGM. Individual remuneration to the CEO is proposed by the Remuneration Committee and approved by the Board of Directors. For other members of the Group management team, individual remuneration is proposed by the CEO and approved by the Board.

Details on the total remuneration and other remuneration that has been granted, directly or indirectly, by the Company to its senior executives is provided in Note 10.

Auditors

The company's auditor is appointed at the AGM. During the year, the auditor meets with the Board of Directors at various times to present their findings based on the audit of the financial statements and internal controls. For the 2023/2024 financial year, Grant Thornton Sweden AB was appointed as the company's auditor, with Stéphanie Ljungberg as the auditor-in-charge. The company's auditor met with the Audit Committee/Board of Directors on four occasions to present the findings and conclusions from their audits.

Internal control and risk management

The Board of Directors is responsible for internal control at Biovica. For financial reporting, internal control and risk management is a process that has been designed by the Board aimed at providing them, management and others within the organization with reasonable assurance about the reliability of external financial reporting and that it has been prepared in accordance with generally accepted accounting principles, applicable laws & regulations and the requirements for listed companies.

Control environment

The internal control environment is based on allocation of responsibilities and authorities among the members of the Board of Directors, Board committees, the CEO and other senior executives. The most important components of Biovica's control environment are documented in the rules of procedure for the Board, instructions to the CEO, policies and other governance documents.

Control activities

Appropriate control activities are a prerequisite for managing the significant risks associated with internal control. In order to safeguard its internal control, Biovica has both automated, system-based controls and manual controls, such as reconciliations and physical inventory counts. Financial analyses of the company's results, along with follow-up on plans and forecasts, supplement the controls and provide an overall confirmation of the quality of reporting. This is monitored continuously throughout the year via reports to the Board and at both Audit Committee meetings and Board meetings.

Internal audit

Biovica has set up a governance and internal control system and activities are carried out at various levels of the company regularly to ensure compliance. Based on that, the Board has assessed that, at the present time, there is no need for setting up a special audit function. The Board reconsiders this decision each year.

Information and communication

The company's governing documents in the form of policies, guidelines and manuals on both internal and external communication are regularly updated and communicated via such things as meetings and other relevant company-internal channels. Biovica's information policy governs communication with external partners, which specifies the guidelines on how information is made public. The aim of the policy is to ensure that the company fully and completely fulfills its information obligations in accordance with the applicable laws and regulations.

Uppsala, dated in accordance with electronic signature

Lars Holmqvist
Chairman of the Board

Annika Carlsson Berg
Board member

Marie-Louise Fjällskog
Board member

Maria Holmlund
Board member

Jarl Ulf Jungnelius
Board member

Jesper Söderqvist
Board member

Anders Rylander
President/CEO, Board member

Board of Directors

Biovica's Board of Directors consists of seven ordinary members elected by the AGM, including the Chairman of the Board, who have been elected for the period until the next Annual General Meeting.

	LARS HOLMQVIST	**ANNIKA CARLSSON BERG**	**MARIE-LOUISE FJÄLLSKOG,** MD, PhD	**MARIA HOLMLUND**
Born	1959	1963	1964	1956
Ordinary member	Chairman of the Board since 2019 and member of the Audit Committee since 2020	Board member since 2021	Board member since 2020	Board member since 2016 and Chairman of the Remuneration Committee since 2020
Citizenship	Swedish	Swedish	Swedish and American	Swedish
Education/background	MBA Mid Sweden University Previously Senior Advisor for healthcare at Bain Capital. Senior management roles at various pharmaceutical and medtech companies, including Agilent, Dako, Applied Biosystems Inc. and Medtronic Europe Sarl.	Annika Carlsson Berg has more than 35 years of experience in the pharmaceutical, biotech, Life Sciences and diagnostics industry, of which, 24 years have been in executive positions. Annika is currently the Chief Quality Officer at Vectura Fertin Pharma. Her prior positions were Global Vice President of Quality Assurance & Regulatory Affairs, at the Division of Immunodiagnostics at Thermo Fisher Scientific, Global Vice President of Quality Assurance, Regulatory Affairs and Medical Affairs at Agilent Technologies, Global Vice President of QA/RA at GE Healthcare and Section Manager at Pfizer. Annika is an analytical chemist and she holds a licentiate's degree in analytical chemistry.	Marie-Louise is an MD (specialist in oncology), having received her degree in medicine from Uppsala University, where she also defended her thesis in 2002 and became Associate Professor of Oncology in 2008. Marie-Louise has more than 30 years of experience in clinical oncology, translational research, and drug development. She is currently the Chief Medical Officer at Faron Pharmaceuticals. Her prior experience includes: CMO at Sensei Biotherapeutics in Boston, USA, Global Clinical Program Leader at Novartis Institute for Biomedical Research (NIBR), where she worked with Translational Clinical Oncology (TCO) and had global responsibility for the development of targeted therapies for CDK4/6, BCL-2, and immunotherapy (CSF-1, PD-1 and CD73). She was also Vice President (VP) Clinical Development at Merus and Infinity Pharmaceuticals, Cambridge, USA.	B.A. in chemistry and biology from Uppsala University and Gothenburg University. M.Sc. from University of North Carolina. More than 30 years of experience working in the field of Life Science and diagnostics. Senior positions in marketing at several major international diagnostic companies.
Current assignments	Board member at: Lundbeck Fonden A/S, H Lundbeck A/S, ALK-Abelló A/S,Life Healthcare Group Holdings Limited and Vitrolife AB.	Chief Quality Officer Vectura Fertin Pharma.	Board member of Faron Pharmaceuticals and Lytix Biopharma AS.	Board member at Prolight Diagnostics AB (publ).
Holding in the company	Directly and indirectly 1,080,417 Class B shares, 181,355 TO3B	19,250 Class B shares, 8,750 TO3B, 25,000 Stock options	25,000 Stock options	31,198 Class B shares, 7,090 TO3B, 25,000 Stock options
Independent in relation to the Company, its management and major shareholders.	Yes	Yes	Yes	Yes

	ULF JUNGNELIUS, MD	**ANDERS RYLANDER**	**JESPER SÖDERQVIST,** PhD
Born	1951	1970	1966
Ordinary member	Board member since 2014 and member of the Remuneration Committee since 2023	Board member since 2010	Board member since 2013 and Chairman of the Audit Committee since 2023
Citizenship	Swedish	Swedish	Swedish
Education/background	Oncology Specialist with diploma from Karolinska Institute, along with clinical experience from Radiumhemmet in Stockholm. Dr. Dr. Jungnelius has extensive experience in international clinical research & development in the field of oncology. He has held executive positions at several international companies such as Eli Lilly, Pfizer, Takeda and Celgene.	M.Sc. in mechanical engineering with focus on industrial economics from KTH Royal Institute of Technology. Previously Senior Manager at Accenture, CTO for ICA AB and founder of Axholmen (consultancy firm).	M.Sc.Eng. from KTH Royal Institute of Technology. Ph.D. in Physics from KTH Royal Institute of Technology and CERN. He has previously held the positions of CEO at Boule Diagnostics, CEO and Board member at Arcoma, Vice President Portfolio Management for Elekta AB's neuroscience division, General Manager for mammography at Philips Healthcare and CEO at Sectra Mamea.
Current assignments	CEO Health Com GmbH (CH), CMO TME Pharma, Styrelseledamot i Ryvu Therapeuticas S.A., Oncopeptides AB.	CEO of Biovica International AB, Board member of Arinvest AB and Anders Rylander Investment AB.	Board member and CEO of Dekatria AB.
Holding in the company	25,000 Stock options	Directly and indirectly 3,636,640 Class A shares, 5,393,484 Class B shares, 1,741,550 TO3B, 50,000 Stock options	Directly and indirectly 41,085 Class A shares and 122,236 Class B shares, 27,780 TO3B, 25,000 Stock options
Independent in relation to the Company, its management and major shareholders.	Yes	Anders Rylander is (via companies and related parties) Biovica's largest shareholder.	Yes

Senior executives

Biovica's executive management team consists of the President/CEO and five additional senior executives. There are four males and two females on the executive management team.

	ANDERS RYLANDER	ANDERS MORÉN	HANNA RITZÉN
Born	1970	1965	1979
Position	CEO since 2011	CFO since 2023	VP R&D since 2022, COO since 2023
Citizenship	Swedish	Swedish	Swedish
Education/background	M.Sc. in mechanical engineering with focus on industrial economics from KTH Royal Institute of Technology. Previously Senior Manager at Accenture, CTO for ICA AB and founder of Axholmen (consultancy firm).	MBA from Uppsala University. Anders has extensive experience as the head of accounting and finance departments at global Life Science and pharmaceutical companies, including Baxter, Roche and Merck and Co Inc. Before joining Biovica, Anders was the Executive Director Finance EMEA Region 1, Australia and Israel at Gilead Sciences.	Hanna has a B.A. in Engineering, focus on chemistry and biotechnology, from Uppsala University. She has 20 years of experience working in the field of Life Science in various R&D management roles, focusing on methodology and product development that supports academia, pharmaceutical companies, contract research organizations and clinical diagnostic companies. She has worked as an expert in measurement quality and participated in many international standardization and harmonization programs. For R&D, she has actively participated and been responsible for many product development programs and the launch of RUO and IVD products. Hanna has also implemented many innovation, product development, customer support and CAPA processes. Before joining Biovica, Hanna worked as Managing Director, Research and Development at Mercodia AB, responsible for strategy, business and organizational development and at Bioanalytisk Serviceverksamhet.
Current assignments	CEO of Biovica International AB, Board member of Arinvest AB and Anders Rylander Investment AB.	Board member at Moréns Ekonomi och Skogsservice AB.	–
Holding in the company	Directly and indirectly 3,636,640 Class A shares, 5,393,484 Class B shares, 1,741,550 TO3B, 50,000 Stock options Anders Rylander is (via companies and related parties) Biovica's largest shareholder.	45,990 Class B shares, 10,450 TO3B	3,100 Class B shares

	HECTOR TAMBURINI	HELLE FISKER	HENRIK WINTHER
Born	1962	1969	1966
Position	Head of US Laboratory Operations, Regulatory & Quality since 2023	VP Commercial and Marketing since 2021	SVP Business Development since 2020
Citizenship	American	Swedish	Swedish
Education/background	M.S. in clinical biochemistry from University of Buenos Aires, Argentina. Hector has more than 35 years of experience in the pharmaceutical, biotechnology and diagnostics industries. Previous roles in management and manufacturing of diagnostic reagents at Prometheus Laboratories, Onconova Therapeutics, Spectrum Pharmaceuticals, Biogen (IDEC) and Roche, in the USA as well as in Buenos Aires, Argentina.	Helle has an MSc Eng in Biotechnology from the Technical University of Denmark (DTU) specializing in immunology and an Executive MBA from Copenhagen Business School. During the last 20 years, she has held a variety of sales and marketing positions at oncology and cancer diagnostic companies and was influential in implementing several global product launches and commercial strategies for such companies as GSK, Dako (now Agilent) and Leica Biosystems, as well as introducing new products in the European markets for small and medium-sized companies, examples of which are ViroGates and Visiopharm. Before joining Biovica, Helle worked as a strategy and marketing consultant on assignments for such clients as Sysmex, Diaceutics, Tieto and Pathcore, working with advanced nuclear, genetic and digital cancer diagnostics and oncology.	Henrik was Associate Professor in Anatomy, Physiology and Cell Biology at University of Copenhagen prior to taking employment at the diagnostics company, Dako, which was later acquired by Agilent. Henrik held several executive management positions at Dako. He was the R&D Director prior to taking over as Business Area Manager for Companion Diagnostics. Under his management, the business area experienced tenfold growth in both revenue and number of employees. At Agilent, Henrik was appointed Vice President and General Manager of the Companion Diagnostics Division. Prior to joining Biovica, Henrik worked at SVP Business Development at the Swedish diagnostics company, Immunovia.
Current assignments	–	Board member at Qlucore AB.	–
Holding in the company	24,000 stock options	37,650 Class B shares, 8,500 TO3B, 20,000 Stock options	32,000 Class B shares

Auditor's report on the corporate governance statement

To the general meeting of the shareholders in Biovica Internatonal AB (publ), corporate identity number 556774–6150.

Engagement and responsibility

It is the board of directors who is responsible for the corporate governance statement for the year the financial year 2023-05-01 – 2024-04-30 on pages 30 - 37 and that it has been prepared in accordance with the Annual Accounts Act.

The scope of the audit

Our examination has been conducted in accordance with FAR's standard RevR 16 The auditor's examination of the corporate governance statement. This means that our examination of the corporate governance statement is different and substantially less in scope than an audit conducted in accordance with International Standards on Auditing and generally accepted auditing standards in Sweden. We believe that the examination has provided us with sufficient basis for our opinions.

Opinion

A corporate governance statement has been prepared. Disclosures in accordance with chapter 6 section 6 the second paragraph points 2-6 the Annual Accounts Act and chapter 7 section 31 the second paragraph the same law are consistent with the annual accounts and the consolidated accounts and are in accordance with the Annual Accounts Act.

Uppsala June 28th 2024

Grant Thornton Sweden AB

Stéphanie Ljungberg
Authorized Public Accountant

Directors' report

2023-05-01—2024-04-30

The Board of Directors and CEO of Biovica International AB (publ), Biovica, CIN 556774-6150, hereby present the annual report and consolidated financial statements for the financial year 1 May 2023 through 30 April 2024. The annual report will be put forth for adoption at the AGM on 17 September 2024. Biovica's class B shares are traded on Nasdaq First North Premier Growth Market. The ticker symbol is BIOVIC. The company's head office is located in Uppsala, Sweden. The annual report has been prepared in SEK and in accordance with International Financial Reporting Standards (IFRS) that have been adopted by the EU.

GENERAL INFORMATION ABOUT THE BUSINESS

Biovica International AB is the Parent Company of a Group that was established in 2009, with the goal of developing and producing a biomarker assay that measures cell proliferation for the benefit of cancer patients and healthcare providers. The Group's head office is in Uppsala, Sweden and it also has an office in San Diego for business in the USA.

Vision and mission

Biovica's vision is to improve the lives of cancer patients via a transformation of how cancer care is monitored by offering innovative biomarker assays.

Financial targets

Within three years of the launch of DiviTum TKa , Biovica's goal is to have achieved a market share of 15 percent of the total market potential in the market segment where the assay has been launched. The total market potential for the USA, Europe and Japan is estimated at USD 400-700 million per year. Launch of DiviTum TKa began in parts of the USA and Europe during the first half of 2023. We continued the launch during the 2023/2024 financial year. Several commercial agreements were signed in the USA, we received pricing decision from CMS/Medicare for DiviTum TKa and signed new partnership agreements for Spain, Portugal and the Nordics. After that, further geographic expansion will occur in Europe and eventually in the Japanese market. Over the next 10 years, Biovica's goal is to claim a market share of 50 percent in the market segments where DiviTumTKa is launched.

Significant events during the 2023/2024 financial year

Extraordinary General Meeting in May 2023:

Decision to issue new stock options (for a maximum amount of 168,000 stock options) and performance share program (for a maximum amount of 56,000 performance shares) for employees in the USA

Biovica signed its first commercial agreement in the USA

On 17 May 2023, Biovica's laboratory in the USA and its subsidiary, Biovica Inc. signed an agreement with MediNcrease Health, which is a nationwide U.S. supplier network and professional association. It makes the assay available and reimbursable to more than 15 million people with insurance coverage through MediNcrease's clients and payers.

DiviTum TKa results presented at ASCO.

The results support the use of DiviTum TKa as a unique biomarker assay that provides important information about patients with hormone receptor (HR)-positive metastatic breast cancer.

Biovica signed its second commercial agreement in the USA

This commercialization agreement makes DiviTum TKa available to customers and members affiliated with Contigo Health.

DiviTumTKa received PLA code for Medicare

The PLA code is a specific code for DiviTumTKa issued by the AMA (American Medical Association). It enables payers and providers to easily identify our product and reduces the administrative burden on them. It is also an important part of the pricing process with Medicare in the USA.

Biovica signed a commercial agreement with Occum Health

The agreement makes DiviTumTKa available to 500 employers using Occum Health for the healthcare solutions they offer to their employees.

Start of a prospective DiviTumTKa trial with Yale

Biovica announced the start of a prospective DiviTumTKa clinical trial in partnership with Yale Cancer Center. The study aims to correlate thymidine kinase activity (TKa) levels, as measured by DiviTum TKa , with medication non-compliance, potential drug-drug interaction issues, and the effects of medication dose reductions in ER/PR-positive HER2-negative metastatic breast cancer patients receiving first-line therapy with a CDK4/6 inhibitor in combination with endocrine therapy.

Biovica signed US agreement with leading healthcare provider in Arizona

Biovica announced that the company has entered into a commercial agreement with a leading healthcare provider that operates more than 30 hospital laboratories, primarily located in Arizona. The agreement will ensure access to DiviTumTKa for patients in the healthcare provider's extensive network covering the southwest region of the United States. This agreement marks Biovica's first commercial hospital (client bill) agreement.

Biovica signed agreement for DiviTumTKa with world-renowned cancer clinic in Florida

This treatment center in Florida is part of a large and well renowned organization that serves all 50 states in US and international representation as well. In total, the organization serves more than 1.3 million patients every year. Florida accounts for approximately 6.5% of the total U.S. population, making it the third-most populous state in the USA. This organization already has a research collaboration with Biovica, resulting in several clinical trials that have been performed.

Biovica received CAP accreditation for its CLIA Laboratory

Biovica received Laboratory Accreditation from the College of American Pathologists (CAP) for its Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in San Diego, California. CAP accreditation is awarded to laboratories that

meet stringent requirements and maintain the highest standards for laboratory operations in terms of quality, accuracy, and consistency, as outlined by CAP. CAP accreditation offers several commercial advantages. It facilitates the process of obtaining reimbursement from private insurance providers and enables DiviTum TKa expansion into New York, Maryland, and Washington D.C. CAP accreditation is also a highly coveted credential, particularly among pharmaceutical and biotechnology companies.

Extraordinary General Meeting in November 2023

A resolution was passed to change the Articles of Association and for a rights issue for a maximum of SEK 120 million. The details are published on the company's website, www.biovica.com.

Biovica signed a commercial partnership agreement with Axlab A/S for commercialization of DiviTumTKa in the Nordics

In the Nordics, approximately 5,700 women are diagnosed with metastatic breast cancer each year. Based on the number of patients with breast cancer, the Nordics account for around 6 percent of the total market potential for the area that consists of the five largest, most populous countries in the EU plus the Nordics. Axlab will lead the Nordic market introduction, where the initial focus will be on breast oncologists and decision-makers creating awareness and demand, along with establishing the assay in guidelines.

Biovica received a final pricing decision on DiviTum TKa from Medicare

The Center for Medicare & Medicaid Services (CMS) announced a final price of USD 322 per test for DiviTum TKa reimbursement with Medicare patients

DiviTumTKa results were presented on three posters at SABCS

New clinical research involving DiviTum TKa was presented at San Antonio Breast Cancer Symposium (SABCS) during 5-9 December 2023. The three posters reinforce how the DiviTum TKa test has value as a response indicator and predictor for hormone receptor-positive (HR+) patients with metastatic breast cancer (MBC) treated with CDK4/6 inhibitors, the most prescribed drug class for this patient population.

Biovica published the results from the rights issue

The subscription rate for the rights issue was thus 83.8 percent, which will generate approximately SEK 100 million in capital to Biovica prior to issue costs.
The details are published on the company's website, www.biovica.com.

Biovica signed a collaboration agreement for DiviTumTKa in Spain and Portugal with the Palex Group

Palex will be leading the introduction and sales of DiviTum TKa in Spain and Portugal, with a focus on creating high awareness and knowledge among breast cancer doctors and other relevant decision makers, as well as incorporating the test into clinical guidelines based on its value to practitioners and patients. This agreement makes the assay available to the more than 8.000 patients who are diagnosed with metastatic breast cancer each year in Spain and Portugal.

Biovica signed master service agreement for TKa testing with leading pharma company

It is a master service agreement with a leading pharmaceutical company for Biovica to provide analyses and services for TKa testing. The agreement opens the door for several new work orders, the first of which is for SEK 1.7 million.

Biovica signed master service agreement for TKa testing with biotech company

It is a master service agreement with a leading biotech company for Biovica to provide analyses and services for TKa testing. The agreement opens the door for several new work orders, the first of which is for SEK 1.7 million.

Interventional DiviTumTKa trial initiated with Washington University.

A clinical trial, BettER, has been launched at Washington University School of Medicine in St. Louis. The study is aimed at evaluating whether patients with HR+ HER2- metastatic or inoperable breast cancer benefit DiviTum TKa. The study seeks to evaluate the impact of early therapeutic switching based on biomarker-driven insights using DiviTum TKa. The study will enroll 50 patients, assessing the effectiveness of modifying treatment based on TKa levels measured at baseline and shortly after treatment initiation. Patients demonstrating insufficient TKa suppression will be recommended for an alternative therapy, potentially enhancing treatment outcomes.

Biovica has received positive patent notification for immunotherapies

Biovica has received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker for immunotherapies (immune checkpoint inhibitor, ICI). This expands the market potential for the DiviTum TKa technology by four to six times.

DiviTum TKa used in observational study at Mayo Clinic in Florida

The study will evaluate DiviTum TKa 's capacity as a predictive blood-based biomarker. Over a period of two years, it will investigate 100 patients with hormone receptor-positive (HR+) metastatic breast cancer undergoing standard of care therapies – either CDK4/6 inhibitors combined with endocrine therapy (ET) or ET monotherapy – providing up to 27 serial samples per patient throughout that time. By conducting real-time serial measurements of thymidine kinase activity (TKa) in conjunction with patient characteristics, tumor features, disease stability, pharmacokinetics, and patient outcomes, the study aims to refine and enhance the precision of treatment approaches.

Biovica will save SEK 30 million/year and is investigating a new go-to-market model in the USA

Biovica has implemented a cost reduction program in Sweden and the USA that will result in savings of SEK 30 million per year, with an associated restructuring cost of SEK 8 million. Biovica is simultaneously investigating a new go-to-market model in the USA of using a partnership model to supplement its own sales force.

Significant events after the end of the period

DiviTum TKa results presented at ASCO, the world's largest cancer conference.

Results with DiviTum TKa from the GEICAM/2014-12 FLIPPER study in Spain were presented at the world's largest cancer conference on 2 June 2024. The data supports the use of DiviTum TKa to predict outcome and progression on first line treatment of HR+ metastatic breast cancer (MBC) patients.

FINANCIAL PERFORMANCE OF THE GROUP

Profit (loss)

Total net sales for 2023/2024 amounted to SEK 7,290 (3,383) thousand, which corresponds to an increase of 115% compared to the previous year. Sales are primarily to customers in the research market, where we have noticed that there is a sharply increasing interest in using DiviTum TKa in the pharmaceutical industry as a biomarker for developing new cancer drugs. Sales for clinical use (IVD) of DiviTum TKa in the USA started up during the year. Those sales amounted to SEK 788 (0) thousand for the year. See Note 6. The company's loss for the year amounts to SEK -124,823 (-110,492) thousand. The net loss for the current year is larger than last year due to the higher cost of having a full sales and marketing organization throughout the entire financial year. Last year, that part of the organization was still being formed. There were also higher costs for commercialization activities, primarily in the USA, along with a restructuring cost of approximately SEK 8 million. Other external costs and employee benefit expenses increased by SEK 16,837 (47,336) thousand compared to last year and for the 2023/2024 financial year amounted to SEK 123,521 (106,684) thousand. The results for the year are lower than the budget that was presented for the 2023/2024 financial year. This is attributable to the delay in the FDA's review of our 510(k) application, which delayed the start of sales in the USA and Europe.

Cash flow

Cash flow from operating activities was SEK -114,575 (-94,640) thousand and total cash flow for the year was SEK -35,658 (24,589) thousand.

Investments

Property, plant and equipment was acquired during the year (in the form of equipment) for SEK 146 (1,206) thousand. These investments primarily pertain to purchases associated with research and development, along with expansion of our premises in Uppsala, as well as equipment for our CLIA laboratory in the USA.

The right-of-use assets amount to SEK 6,935 (9,875). See Note 16 for more details. During the year, the net amount of investments in intangible assets, consisting of R&D costs and patents was SEK 0 (1,573) thousand. The change is due to the fact that the current version of DiviTum TKa has reached final development. For details on impairment testing, please see Note 4.

Financial position

The closing amount for cash & cash equivalents on 30 April 2024 was SEK 79,407 (114,327) thousand. In December 2023, a rights issue was completed to secure capital for the company's ongoing launch of DiviTum TKa. The rights issue raised capital of SEK 100 million prior to issue costs. Biovica currently has cash holdings of SEK 79 million and is anticipating additional funds from warrants from series TO3B (more information about that can be found in the section, Shares). In April 2024, a cost saving program of SEK 30 million with restructuring costs of approximately SEK 8 million was announced (more information about that can be found in the press release). Taking all of that into consideration, it has been assessed that the company will become cash flow positive during the second half of 2025. If the warrants from series TO3B are not fully exercised, there is a risk that cash will be insufficient for getting the company to the point when it is cash flow positive. Accordingly, at the time of publishing this Annual Report, the company has not secured the necessary funding for at least the next twelve months. The Board is working with different scenarios to secure financing should that outcome occur. The Board is evaluating various financing alternatives that will secure continued operations, with the goal of choosing the most attractive solution from the perspective of both the company and its shareholders. The Board and management have concluded that there are very favorable conditions for obtaining the necessary capital during fall 2024 if warrants from series TO3B are not fully exercised.

Equity at the end of the period was SEK 96,640 (138,636) thousand and the equity ratio was 74 (80) percent. No dividends have been proposed for the 2023/2024 financial year.

Parent Company

The figures reported for the Parent Company are essentially the same as those reported for the Group in terms of sales, which, for the Parent Company also include intra-Group sales to the U.S. subsidiary, Biovica Inc. The Parent Company's balance sheet total was SEK 122,867 (158,305). Other comments for the Group thus also apply to the Parent Company.

Subsidiaries

Biovica Inc. has offices and a CLIA laboratory in San Diego, USA. It conducts marketing and sales activities for DiviTum TKa tests using through its own sales force. These activities are directed at healthcare providers treating patients with metastatic breast cancer in the USA. The CLIA laboratory analyses samples from the clinical tests on patients (IVD) as well as from research and development tests submitted by research institutions and the research pharmaceutical industry (RUO or Research Use Only).

Biovica Services AB does not currently have any operations.

The work of the Board

At the 2023 AGM, a total of seven Board members were elected: Lars Holmqvist, Marie-Louise Fjällskog, Maria Holmlund, Ulf Jungnelius, Anders Rylander, Annika Carlsson Berg and Jesper Söderqvist. Lars Holmqvist was elected as the new Chairman of the Board. During the year, the Board held 23 meetings and it also set up two committees. Biovica thus now has a Remuneration Committee and an Audit Committee. The Board dealt with such matters as financing and financial reporting. The Board is responsible for the company's organization and administration, along with continuously assessing the company's financial situation. The Board has adopted a written rules of procedure document which regulates such things as Board meetings, matters to be submitted to the Board, financial reports and instructions to the CEO.

Corporate governance report

The corporate governance report is prepared separately and presented on pages 30-37 of the printed version of the annual report.

Employees

The average number of employees for the year was 37 (31) employees, of which 18 (14) are female.

Sustainability

See the separate section on Biovica's sustainability work on page 26-27 of the printed version of the annual report.

Share and share capital

The company has both Class A shares (each worth 3 votes) and Class B shares (each worth 1 vote). The company has registered share capital of SEK 5,603,704 allocated between 6,271,293 Class A shares and

77,784,267 Class B shares. The quotient value is SEK 0.07 per share. During the year, (0) 5,000 Class A shares were converted to Class B shares in accordance with what has been stipulated in the Articles of Incorporation. This may occur at the end of each quarter until there are no longer any Class A shares registered.

At the EGM on 17 May 2023, it was resolved to implement two new incentive programs,2023/2026:1 and 2023/2026:2 for employees working at the company's US subsidiary. More information is available in Note 23.

At the 2023 AGM, it was decided to implement four new incentive programs. 2023/2026:3, 2023/2026:4, 2023/2026:5 and 2023/2026:6. These programs have never been awarded. More information is available in Note 25.

In December 2023, a total of 38,314,166 Class B shares were subscribed for in conjunction with the rights issue. The subscription price was SEK 2.61. In total, the company's share capital increased because of the rights issue by SEK 2,554,278, generating approximately SEK 100 million for the company before issue costs. Shareholders who participated in the rights issue were issued, free-of-charge, an additional 5 warrants of series TO3B for each share they subscribed for. One (1) warrant from series TO3 B entitles the holder to subscribe for one (1) newly issued share during during the period 12 September 2024 through 30 September 2024. The subscription price is SEK 2.61. If all warrants from series TO3B are fully exercised, the company's share capital would increase by SEK 1,161,035, generating an additional SEK 45.4 million before issue costs. For more details on TO3B, please see the prospectus for the rights issue, which is published on the company's website.

A table showing share capital performance is presented on page 29 of the printed version of the Annual Report.

Major shareholders

Anders Rylander, CEO and member of Biovica's Board of Directors owns approximately 11% of Biovica's shares, which corresponds to approximately 17% of the votes in the Biovica.

Related party transactions

During the year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid was SEK 271 (230) thousand.

Expected future development

Biovica's business plan aims to launch DiviTum TKa in the clinical market for monitoring metastatic breast cancer. The first market launch of DiviTum TKa occurred during March-April 2023 and the initial feedback from leading oncologists has been very positive. The decision to own and run its own CLIA laboratory in San Diego enables Biovica to more effectively develop the sales and reimbursement process for DiviTum TKa. It gives Biovica more control over the pricing, to ensure that it reflects the value and benefits to payers, doctors and patients, thereby facilitating better margins in the US market. The Board decided in April to implement a cost reduction program in both Sweden and the USA that will result in savings of SEK 30 million per year, with an associated restructuring cost of SEK 8 million. Biovica is simultaneously investigating a new go-to-market model in the USA of using a partnership model to supplement its own sales force. The goal is to become cash flow positive during 2025.

Launch of DiviTum TKa in Europe occurred during the same period via partners in the Netherlands, Poland and Italy. During the financial year, additional agreements were signed for Spain, Portugal and the Nordics. Additional agreements for commercialization of DiviTum TKa in selected markets in Europe are progressing in accordance with plan.

Biovica currently has around 20 customers that have signed a master service agreement (MSA) with Biovica. These are companies in the global pharmaceutical industry, where Biovica provides analysis services for research purposes and clinical trials. We have noticed that there is a strong growing interest from the global pharmaceutical industry for the use of DiviTum TKa as a biomarker for measuring cell proliferation and response to treatment. Biovica recently received a positive International Preliminary Report on Patentability (IPRP) covering the use of TKa as a prognostic and monitoring marker for immunotherapies (immune checkpoint inhibitor, ICI). This expands the market potential for the DiviTum TKa technology by four to six times. Our assessment is that this market has great potential for future growth.

Significant risks and uncertainties

In general, the Group's risks can be grouped into two categories, which are operational risks related to business activities and risks related to financing activities. The Board is responsible for ensuring that the Group manages its risks in the right way and that there is compliance with the established principles for financial reporting and internal control.

In Note 3 of this annual report, Biovica lists the company's main financial risks and explains which measures are in place to mitigate those risks. A summary of other business risks is presented below.

Regulatory risk

Having obtained FDA 510k Clearance for DiviTum TKa in July 2022, CLIA Certification in February 2023 and CAP accreditation in October 2023 for our fully owned laboratory, the assessed regulatory risk for DiviTum TKa is low.

Financing and inadequate working capital

There is also a risk that Biovica will not succeed in attracting the capital it requires for implementing its business plan. That could delay or constrict commercial activities and result in lower sales than what the company is aiming for in the business plan that has been adopted for 2024/2025. Deterioration of the economic situation towards the end of 2022 and rising interest rates has meant that this risk has increased compared to last year. Biovica currently has cash holdings of SEK 79 million and is anticipating additional funds from the exercise of warrants from series TO3B (more information about that can be found in the section, Shares). In April 2024, a cost saving program of SEK 30 million with restructuring costs of approximately SEK 8 million was announced. Taking all of that into consideration, it has been assessed that the company will become cash flow positive during the second half of 2025. If the warrants from series TO3B are not fully exercised, there is a risk that cash will be insufficient for getting the company to the point when it is cash flow positive. Accordingly, at the time of publishing this Annual Report, the company has not secured the necessary funding for at least the next twelve months. The Board is working with different scenarios to secure financing should that outcome occur. The Board is evaluating various financing alternatives that will secure continued operations, aimed at choosing the most attractive solution from the perspective of both the company and its shareholders. Please see the comments on Financial position on page 41.

Employees

Biovica is highly dependent on key employees. There is a risk of the company's projects becoming delayed or not being able to complete them if these key employees leave the company or, for some other reason, are unable to perform their assigned tasks.

Uncertainties in the global situation

At present, management's assessment is that Biovica is not impacted by Russia's invasion of Ukraine or the war in Gaza. The Board and management team are monitoring the situation closely but the current assessment is that the wars have very little impact on Biovica's operations. War does, however, impact global supply chains, which could lead to delivery problems for our suppliers and customers and that is something that could cause significant problems.

R&D activities

Biovica develops and commercializes blood-based biomarker assays for evaluating the effect of cancer treatments. Biovica's DiviTum TKa measures the cell proliferation rate and clinical studies have shown that it can quickly reveal whether treatment is effective. Nearly half of Biovica's employees work in the R&D department.

Environmental impact

Biovica does not run any environmentally hazardous activities requiring a permit or obligation to report in accordance with the Swedish Environmental Code.

Dividends

The Board proposes that no dividends shall be paid for the 2023/2024 financial year.

Proposal for appropriation of funds

The Board proposes that the available funds of SEK 64,238,276 are appropriated as follows:

accumulated losses	-353,316,575
share premium reserve	543,918,107
loss for the year	-126,363,256
Retained funds at year-end	**64,238,276**
Amount to be carried forward	64,238,276

For further information on the company's profit (loss) and financial position, please see the accompanying income statements, balance sheets and supplementary disclosures.

MULTI-YEAR COMPARISON FOR THE GROUP

All amounts are in SEK thousands, unless otherwise stated	2023/2024	2022/2023	2021/2022	2020/2021	2019/2020
Net sales	7,290	3,383	2,045	2,077	1,671
Operating profit (loss)	-126,845	-110,457	-60,101	-40,181	-29,816
Profit (loss) for the period	-124,823	-110,492	-60,003	-39,483	-30,318
Cash and cash equivalents	79,407	114,327	89,792	145,364	40,777
Equity	96,640	138,636	124,088	182,661	78,217
Total assets	131,408	172,288	151,631	192,650	90,259
Equity ratio, %	74	80	82	95	87
Number of employees	37	31	20	20	17
Number of shares at the end of the period	84,055,560	45,741,394	28,488,372	28,418,372	23,573,372

Definitions

Equity ratio = adjusted equity as a percentage of total assets

MULTI-YEAR COMPARISON FOR THE PARENT COMPANY

All amounts are in SEK thousands, unless otherwise stated	2023/2024	2022/2023	2021/2022	2020/2021	2019/2020
Net sales	27,965	10,817	2,045	2,077	1,671
Operating profit (loss)	-128,701	-110,120	-61,871	-41,907	-30,312
Profit (loss) for the period	-126,363	-109,800	-60,540	-40,004	-30,571
Cash and cash equivalents	77,105	106,006	86,811	142,920	39,642
Equity	94,227	138,056	122,816	182,061	78,117
Total assets	122,867	158,305	137,255	189,748	86,292
Equity ratio, %	77	87	89	96	91
Number of employees	24	22	19	19	16
Number of shares at the end of the period	84,055,560	45,741,394	28,488,372	28,418,372	23,573,372

KEY PERFORMANCE INDICATORS FOR THE GROUP

SEK thousands	2023/2024	2022/2023	2021/2022	2020/2021	2019/2020
Net sales	7,290	3,383	2,045	2,077	1,671
Operating profit (loss)	-126,845	-110,457	-60,101	-40,181	-29,816
Profit (loss) for the year	-124,823	-110,492	-60,003	-39,483	-30,318
Capitalized R&D costs	–	1,573	2,992	3,560	7,035
Capitalized R&D expenditure as a percentage of operating expenses	0	-1	-5	-8	-20
Earnings per share, before dilution	-2.14	-3.17	-2.11	-1.39	-1.29
Earnings per share, after dilution	-2.14	-3.17	-2.11	-1.39	-1.29
Cash and cash equivalents at the end of the period	79,407	114,327	89,792	145,364	40,777
Cash flow from operating activities	-114,575	-94,640	-52,126	-34,409	-24,782
Cash flow for the period	-35,658	24,589	-55,659	104,692	23,926
Equity	96,640	138,636	124,088	182,661	78,217
Equity per share	1.15	3.98	4.3	6.43	3.32
Equity ratio (%)	74	80	82	95	87
Average number of employees	37	31	25	20	17

The Group was established in 2009 by setting up the subsidiary company, Biovica Services AB. The Group now also has a subsidiary, Biovica Inc., in the USA, see Note 19.

ALTERNATIVE KEY PERFORMANCE INDICATORS

Of the KPIs presented above, the only one that is obligatory to report, and which is defined in accordance with IFRS is: Earnings per share, before and after dilution. For the other KPIs, the following are in accordance with IFRS presentation requirements: Profit (loss) for the year, Cash & cash equivalents at the end of the period, Cash flow for the period and Equity.

KPIs	Definition	Reason for using alternative KPIs, which are not defined in accordance with IFRS.
Net sales	Income from goods sold	Shows the demand for the product.
Operating profit (loss)	Profit (loss) before financial items and tax.	Operating profit (loss) is an indication of the company's earnings generated from ordinary operations.
Earnings per share, before and after dilution	Profit (loss) divided by the weighted average number of shares during the period, before and after dilution.	
Cash & cash equivalents and short-term investments	Bank balances and short-term investments.	
Cash flow from operating activities	Cash flow before the cash flow from investing activities and financing activities.	
Cash flow for the period	Change in cash & cash equivalents for the period not including the effect from unrealized exchange gains and losses.	
Equity per share	Equity divided by the number of shares at the end of the period.	Management uses this KPI to monitor the value of equity per share.
Equity ratio	Equity as a percentage of total assets.	Management uses this KPI because it provides an indication of the company's financial stability.
Average number of employees	The average number of employees is calculated as the average during the period of the number of employees per month.	

Consolidated income statement and statement of comprehensive income

SEK thousands	Note	May-April 2023/2024	May-April 2022/2023
Net sales	*5, 6*	7,290	3,383
Other operating income	*8*	1,013	739
Work performed by the company and capitalized		–	1,573
Total revenue		**8,304**	**5,696**
Materials cost		-413	-340
Other external costs	*9*	-37,523	-39,230
Employee benefit expenses	*10*	-85,998	-67,455
Depreciation/amortization of property, plant and equipment and intangible assets		-9,429	-8,214
Other expenses		-1,785	-914
Operating profit (loss)		**-126,845**	**-110,457**
Financial income	*11*	2,998	271
Financial expenses	*11*	-289	-493
Profit (loss) before tax		**-124,136**	**-110,680**
Tax expense	*13*	-687	187
Profit (loss) for the year		**-124,823**	**-110,492**
Consolidated statement of comprehensive income			
Profit (loss) for the year		-124,823	-110,492
Items that may be subsequently reclassified to profit and loss			
Exchange differences when translating foreign operations		294	0
Comprehensive income for the year (loss)		**-124,530**	**-110,492**
Earnings per share	*23*		
Earnings per share, before dilution (SEK)		-2.14	-3.17
Average number of shares, before dilution		58,408,099	34,828,207
Earnings per share, after dilution (SEK)		-2.14	-3.17
Average number of shares, after dilution		58,408,099	34,828,207

Consolidated statement of financial position

SEK thousands	Note	2024-04-30	2023-04-30
ASSETS			
Intangible assets			
Capitalized expenditure for R&D	*14*	29,400	29,400
Patents	*15*	2,203	2,203
Total intangible assets		*31,602*	*31,602*
Property, plant and equipment			
Machinery, equipment, tools, fixtures and fittings	*16*	1,179	1,336
Right-of-use assets	*17*	6,935	9,875
Total property, plant and equipment		*8,114*	*11,210*
Financial assets			
Deferred tax asset		449	–
Deferred tax asset	*18*	3,127	3,668
Total financial assets		*3,576*	*3,668*
Total fixed assets		**43,292**	**52,298**
Inventories		2,199	1,358
Current receivables			
Accounts receivable		1,667	577
Other receivables		1,659	968
Prepaid expenses and accrued income		3,184	2,759
Cash & cash equivalents including short-term investments	*29*	79,407	114,327
Total current assets		**88,115**	**119,990**
TOTAL ASSETS		**131,408**	**172,288**
EQUITY			
Share capital	*22, 23*	5,604	3,049
Other contributed capital	*23*	543,918	463,938
Reserves		410	116
Retained earnings (losses), including loss for the year		-453,291	-328,468
Total equity		**96,640**	**138,636**
LIABILITIES			
Lease liabilities	*17*	4,296	7,304
Deferred tax liability	*18*	2,180	2,710
Total non-current liabilities		**6,476**	**10,014**
Lease liabilities	*17*	3,532	3,149
Advance payments from customers		19	231
Accounts payable		3,028	3,277
Current tax liabilities		229	824
Other liabilities		1,181	984
Accrued expenses and deferred income		20,303	15,172
Total current liabilities		**28,291**	**23,638**
TOTAL EQUITY AND LIABILITIES		**131,408**	**172,288**

Consolidated statement of changes in equity

SEK thousands	Share capital	Other contributed capital	Reserves	Retained earnings	Total equity
Opening balance, 1 May 2022	**1,899**	**340,049**	**115**	**-217,975**	**124,088**
New issue of shares via					
– exercise of warrants	5	1,367			1,373
– subscription of new shares	1,145	147,572			148,717
Issue fees		-25,177			-25,177
Share-based payments, employees		127			127
Transaction with owners	**3,049**	**463,938**	**115**	**-217,975**	**249,128**
Profit (loss) for the year				-110,492	-110,492
Other comprehensive income			0		0
Comprehensive income for the year (loss)	**–**	**–**	**0**	**-110,492**	**-110,492**
Closing balance, 30 April 2023	**3,049**	**463,938**	**116**	**-328,468**	**138,636**
Opening balance, 1 May 2023	**3,049**	**463,938**	**116**	**-328,468**	**138,636**
New issue of shares via					
– subscription of new shares	2,554	96,566			99,121
Issue fees		-16,650			-16,650
Share-based payments, employees		64			64
Transaction with owners	**5,604**	**543,918**	**116**	**-328,468**	**221,170**
Profit (loss) for the year				-124,823	-124,823
Other comprehensive income			294		294
Comprehensive income for the year (loss)	**–**	**–**	**294**	**-124,823**	**-124,530**
Closing balance, 30 April 2024	**5,604**	**543,918**	**410**	**-453,291**	**96,640**

Consolidated statement of cash flows

SEK thousands	Note	May-April 2023/2024	May-April 2022/2023
Operating profit (loss)		-126,845	-110,457
Depreciation/amortization of property, plant and equipment and intangible assets	*14, 15, 16, 17*	9,429	8,214
Other non-cash items	*26*	367	7
Interest received	*11*	2,271	271
Interest paid	*11*	-289	-453
Income tax paid		-2,230	90
Change in current receivables		-398	-716
Change in current liabilities		3,708	8,306
Change in inventories		-588	99
Cash flow from operating activities		**-114,575**	**-94,640**
Investments in intangible assets	*14.15*	–	-1,573
Investments in PPE	*16.17*	-146	-1,206
Investments in financial assets		-439	–
Cash flow from investing activities		***-585***	***-2,779***
New share issue	*23*	99,121	150,090
Issue fees	*23*	-16,650	-25,177
Amortization of lease liabilities		-2,968	-2,904
Cash flow from financing activities		***79,502***	***122,009***
Cash flow for the year		**-35,658**	**24,589**
Cash and cash equivalents at the beginning of the year		114,327	89,792
Translation difference, cash and cash equivalents		737	-54
Cash and cash equivalents at the end of the year	*29*	79,407	114,327

Parent Company income statement

SEK thousands	Note	May-April 2023/2024	May-April 2022/2023
Net sales	*5, 6*	27,965	10,817
Work performed by the company and capitalized		–	1,573
Other operating income	*8*	1,013	739
Total revenue		**28,979**	**13,129**
Materials cost		74	-416
Other external costs	*7, 9, 12, 17*	-114,721	-86,130
Employee benefit expenses	*10*	-35,281	-30,952
Depreciation/amortization of property, plant and equipment and intangible assets		-5,966	-4,837
Other operating expenses		-1,785	-914
Operating profit (loss)		**-128,701**	**-110,120**
Other interest income and similar items	*11*	2,338	480
Interest expenses and similar items	*11*	0	-160
Profit (loss) after financial items		**-126,363**	**-109,800**
Income tax	*13*	–	–
Profit (loss) for the year		**-126,363**	**-109,800**

The Parent Company's statement of comprehensive income is consistent with profit or loss for the year.

Parent Company balance sheet

SEK thousands	Note	2023-04-30	2022-04-30
ASSETS			
Intangible assets			
Capitalized expenditure for R&D	*14*	29,400	34,488
Patents	*15*	2,203	2,932
Total intangible assets		*31,602*	*37,420*
Property, plant and equipment			
Machinery, equipment, tools, fixtures and fittings	*16*	499	502
Total property, plant and equipment		*499*	*502*
Financial assets			
Participations in Group companies	*19*	108	108
Receivables from Group companies	*20*	7,498	9,911
Total financial assets		*7,606*	*10,019*
Total fixed assets		**39,707**	**47,940**
Inventories		2,122	1,358
Current receivables			
Accounts receivable		1,066	577
Other receivables		607	871
Prepaid expenses and accrued income		2,259	1,552
Cash & cash equivalents and short-term investments	*29*	77,105	106,006
Total current assets		**83,159**	**110,364**
TOTAL ASSETS		**122,867**	**158,305**
EQUITY			
Restricted equity			
Share capital	*22, 23*	5,604	3,049
Fund for development expenditure		24,385	27,722
Total restricted equity		*29,989*	*30,771*
Non-restricted equity			
Share premium reserve		543,918	463,938
Capitalized gain or loss		-353,317	-246,854
Profit (loss) for the year		-126,363	-109,800
Total non-restricted equity		*64,238*	*107,285*
Total equity		**94,227**	**138,056**
LIABILITIES			
Prepayments from customers and prepaid grants		19	231
Accounts payable		1,486	1,953
Liability to Group companies		15,606	9,424
Current tax liabilities		229	215
Other liabilities		977	800
Accrued expenses and deferred income		10,323	7,626
Total current liabilities		**28,640**	**20,248**
TOTAL EQUITY AND LIABILITIES		**122,867**	**158,305**

Parent Company statement of changes in equity

SEK thousands	Share capital	Fund for development expenditure	Share premium reserve	Retained earnings	Profit (loss) for the year	Total equity
Opening balance, 1 May 2022	**1,899**	**28,174**	**340,048**	**-186,765**	**-60,540**	**122,816**
Appropriation in accordance AGM decision				-60,540	60,540	–
Capitalized development expenditure for the year	–	-452		452		–
New issue of shares via						
– exercise of warrants	5		1,367			1,373
– subscription of new shares	1,145		147,572			148,717
Issue fees			-25,177			-25,177
Share-based payments, employees			127			127
Profit (loss) for the year					-109,800	-109,800
Closing balance, 30 April 2023	**3,049**	**27,722**	**463,938**	**-246,854**	**-109,800**	**138,056**

Opening balance, 1 May 2023	**3,049**	**27,722**	**463,938**	**-246,854**	**-109,800**	**138,056**
Appropriation in accordance AGM decision				-109,800	109,800	–
Capitalized development expenditure for the year		-3,337		3,337		–
New issue of shares via						–
– subscription of new shares	2,554		96,566			99,121
Issue fees			-16,650			-16,650
Share-based payments, employees			64			64
Profit (loss) for the year					-126,363	-126,363
Closing balance, 30 April 2024	**5,604**	**24,385**	**543,918**	**-353,317**	**-126,363**	**94,227**

Parent Company statement of cash flows

SEK thousands		May-April 2022/2023	May-April 2021/2022
Operating profit (loss)		-128,701	-110,120
Depreciation/amortization of property, plant and equipment and intangible assets	*14, 15, 16*	5,966	4,837
Interest received	*11*	1,863	480
Interest paid	*11*	0	-172
Other non-cash items	*26*	385	68
Income tax paid		14	130
Change in current receivables		-932	-10
Change in current liabilities		8,378	5,678
Change in inventories		-764	174
Cash flow from operating activities		**-113,792**	**-98,934**
Investing activities			
Investments in intangible assets	*14, 15*	–	-1,573
Investments in PPE	*16*	-146	-201
Investments in financial assets	*20, 21*	2,413	-5,082
Cash flow from investing activities		*2,267*	*-6,856*
Financing activities			
New share issue	*23*	99,121	150,090
Issue fees	*23*	-16,650	-25,177
Cash flow from financing activities		*82,470*	*124,912*
Cash flow for the year		**-29,054**	**19,122**
Cash and cash equivalents at the beginning of the year		106,006	86,811
Translation difference, cash and cash equivalents		154	72
Cash and cash equivalents at the end of the year	*29*	77,105	106,006

Supplementary disclosures

NOTE 1 GENERAL INFORMATION

Biovica International AB (Biovica) is the Parent Company for the Group and it is a public limited liability company with registered office in Uppsala, Sweden. The head office and its primarily place of establishment is: Dag Hammarskjölds väg 54B, 752 37 Uppsala, Sweden. Biovica's shares are traded on Nasdaq First North Premier Growth Market, Stockholm.

NOTE 2 SIGNIFICANT ACCOUNTING AND VALUATION PRINCIPLES

The consolidated financial statements have been prepared in accordance with the Swedish Annual Accounts Act and RFR 1 Supplementary Accounting Rules for Groups and the International Financial Reporting Standards (IFRS) that have been adopted by the EU. The financial statements have been prepared under the assumption that the Group runs its operations in accordance with the going concern principle.
The consolidated financial statements for the reporting period that ended on 30 April 2024 (including comparison figures) were approved by the Board on 28 June 2024.
The Parent Company applies the same accounting policies as the Group, except for the items presented in the section called "Parent Company accounting policies".

Valuation and classification
Assets and liabilities are reported at historical cost, except for financial assets and financial liabilities, which are measured at amortized cost. Short-term investments (funds) are measured at fair value via profit of loss.

Functional currency and reporting currency
The Parent Company's functional currency is SEK, which is also the reporting currency for the Parent Company and the Group. Accordingly, the financial statements are presented in SEK. All amounts, unless otherwise stated, are rounded to the nearest thousand.

Assessments and estimates in the financial statements
In preparing the financial statements, the executive management team must make assessments and estimates that affect both the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. The actual outcome may deviate from these estimates and assessments.
Estimates and assessments are regularly reviewed. A change in estimates and assumptions is reported in the period when the change is made if it only impacts that period. Otherwise, it is reported in the period when the change is made and in future periods if it impacts both the current period and future periods.
Assessments and estimates that have a significant impact on the financial statements and which could lead to material adjustments in future financial statements are described in more detail in Note 4.

Significant accounting policies
This note details the significant accounting policies that have been applied during preparation of the consolidated financial statements. Unless otherwise stated, these policies have been applied consistently for all years presented in the report. The consolidated financial statements cover Biovica International AB and its subsidiaries.

(i) Changes in accounting policies resulting from new or revised IFRS
New and amended standards and interpretations that are applicable from 2023 and which have had an impact on the Group's annual report are changes in disclosure requirements for accounting principles, according to IAS 1. Fewer disclosures are now required and only disclosures on significant accounting policies are included.

(ii) New IFRS that have not yet been applied
None of the other IFRS or IFRIC interpretations that have yet to enter into force are expected to have a significant impact on the Group.

Consolidated financial statements
Subsidiaries are all companies in which the Group has a controlling interest. The Group has a controlling interest over a company when it is exposed to, or entitled to a variable return from, its holding in the company and it is able to affect such return via its controlling interest over the company.
The acquisition method is used for reporting the Group's business combinations. The accounting policies for subsidiaries have, in some instances, been revised to ensure that they are consistent with the Group's policies.

Segment reporting
The Group's operations consist of development, manufacturing and sales of blood analysis products. The Group's organizational structure is by function as follows: production, sales & marketing, administration and R&D. The Group is considered to be a single unit, where all of its sub-components are integrated and dependent upon each other. Biovica's highest decision-making body monitors the consolidated income statement and statement of comprehensive income. More information is provided in Note 6, Segment reporting.

Revenue from contracts with customers
Revenue from contracts with customers is reported at net realizable value and recognized when the performance obligation has been fulfilled and control over the goods or services has been transferred to the customer, in accordance with IFRS 15. This assessment shall occur from the customer's perspective, taking into consideration such things as transfer of ownership and risks, the customer's acceptance, physical access and the right to invoice. An assessment must also be made of whether control has been transferred at a specific point in time, or over time. Most of Biovica's agreements with customers pertain to product sales. The products are regarded as separate and distinct performance obligations. Revenue is recognized at net realizable value at a specific point in time, which is when control of the goods or services has been transferred to the customer.
The contract terms and conditions may vary but typically, transfer of control and thus revenue recognition occurs at the time of delivery.

Agreements with customers where the performance obligation has not yet been fulfilled
Biovica does not have any agreements with customers that extend beyond one year, which is why the simplification rule has been applied. It means that disclosures do not need to be made on the scope of agreements with customers where the performance obligation has not yet been fulfilled.

Reporting of government grants
Government grants are reported at fair value when there is reasonable certainty that the terms associated with the grant can be met and accordingly, that the grant will be paid. Grants that have been received to cover expenses are reported under the heading "other income" in the same period that the expenses arise. Grants attributable to an asset reduce the asset's value in the balance sheet. Grants that have been received, but for which the terms have not yet been met are reported in *Prepayments from customers and prepaid grants.*

Financial income and expenses
Financial income consists of interest earned on cash & cash equivalents. Interest income on financial instruments is reported using the effective interest method. When making the calculation, all payments made and received between the parties to the contract are considered that are a

part of the effective interest, transaction costs and all other premiums and discounts.
Financial expenses consist of interest on loans. Borrowing costs are recognized in profit or loss using the effective interest method except to the extent that they are directly attributable to the purchase, design or production of an asset that takes a considerable amount of time to complete for its intended use or sale (such costs are instead included in the cost of acquisition for the asset).
Foreign exchange gains and losses attributable to assets and liabilities associated with financing activities are reported net.

Deferred tax
Temporary differences attributable to participations in subsidiaries and associated companies that are not expected to be reversed in the near future are not included.
Deferred tax assets relating to deductible temporary differences and loss carryforwards are only reported to the extent that it is probable that they will be utilized.

Financial instruments
Financial instruments reported in the balance sheet include, on the asset side, cash & cash equivalents, short-term investments, accounts receivable and other receivables. On the liability side, there are accounts payable, other liabilities and accrued expenses.

Recognition and derecognition in the balance sheet
Financial assets and liabilities are reported in Biovica's balance sheet when the company becomes party to the instrument's contractual terms. An asset (receivable) is recognized in Biovica's balance sheet when there is a contractual obligation for the counterparty to pay, even if the invoice has not yet been sent. Accounts receivable are recognized in the balance sheet when the invoice has been sent. A liability is recognized in Biovica's balance sheet when there is a contractual obligation for the counterparty to pay, even if the invoice has not yet been sent. Accounts payable are recognized when the invoice has been received. A financial asset is removed from the balance sheet when the rights in the contract are realized, mature, or when Biovica loses control over them. The same applies to a portion of a financial asset. A financial liability is removed from the balance sheet when the obligations have been settled, canceled or in some other manner extinguished. The same applies to a portion of a financial liability. Financial assets and liabilities are offset and reported at a net sum in the balance sheet, only when there is a legally enforceable right to offset the amounts and an intention either to settle on a net basis, or to realize the asset and settle the liability simultaneously.

Measurement at initial recognition
All financial instruments are initially measured at fair value plus or minus transaction costs. However, for financial instruments that are, on an ongoing basis, measured at fair value through profit or loss, the transaction costs are instead expensed as incurred. Accounts receivable (without a significant financing component) are initially measured at the transaction amount that is established in accordance with IFRS 15.

Financial assets
All financial assets are measured at amortized cost except short-term investments, which are measured at fair value through profit or loss. This is because they are held in accordance with a business model for which the goal is to obtain the contractual cash flows. Furthermore, the cash flows from these assets consist solely of payments of principal amounts and interest.

Financial liabilities
Financial liabilities are classified as measured at amortized cost or at fair value through profit or loss. All other financial liabilities are measured at amortized cost using the effective interest method.

Property, plant and equipment
The Group applies component depreciation, which means that the estimated useful life of the component is the basis for depreciation.

The following estimated useful lives are applied:
- plant and machinery: 5 years
- equipment, tools, fixtures and fittings: 5 years

Leased assets
The Group primarily leases premises and cars. The term of lease agreements for premises currently varies between 60-90 months, including likely extension periods. Cars are typically leased for 36 months. Leased assets may not be used as collateral for loans. In some instances, an extension is possible, see below for more information.
A right-of-use agreement is reported as an asset and corresponding liability as of the date when the leased asset is available to the Group. Lease payments are divided into amortization of the liability and interest expense. The interest expense for each period is calculated using the annuity method. Right-of-use assets are depreciated on a straight-line basis over the useful life. Assets and liabilities attributable to leasing are initially measured at fair value.
Payments attributable to short-term agreements or leases for which the underlying asset is of low value are expensed in the income statement. Short-term agreements are those with a term that does not exceed 12 months. Management has assessed that agreements where the underlying asset is of low value pertain to simple machinery and office equipment.
The lease term consists of the non-cancellable portion of the lease plus possible extension options if, at inception of the lease, it is reasonably certain that they will be exercised.

Intangible assets
Research and development
Expenditure for research that is for the purpose of gaining new scientific or technical knowledge is expensed as incurred. Expenditure for development (where the research results or other knowledge is used to achieve new or improved products or processes) is recognized as an intangible fixed asset in the statement of financial position if the product or process is technically or commercially usable and the company has adequate resources for monitoring the development and thereafter using or selling the intangible asset. Decisions on whether or not to capitalize expenditure on development projects are made by the company's Board of Directors based on documentation and support provided by the Audit Committee. The decision is based on whether it is possible to implement the project using existing or future resources and on whether conclusion of the project and launch is expected to occur in the foreseeable future.
Directly attributable expenditure that is capitalized as part of the cost of the asset includes expenditure for employees and materials. With capitalization, consideration is given to the portion of expenditure recognized as revenue against received/expected grants. Capitalized development expenditure is reported as intangible assets and amortized as of the date when the asset is ready for use. Other expenditure for development is expensed as incurred and recognized in profit or loss for the year.

Patents
Patents are recognized at the cost of acquisition and they are amortized on a straight-line basis over their estimated useful lives. The estimated useful life is assessed based on the legal life of the patent.

Amortization
The estimated useful life for capitalized development expenditure is 10 years.

Inventories
Inventories are measured at the lower of cost and net realizable value. The cost of acquisition for inventories is measured using the FIFO method and it includes expenses associated with the acquisition of inventory assets, along with transportation costs for bringing them to their current location and condition. For manufactured goods and work-in-progress, the cost of acquisition includes a reasonable share of the indirect costs based on normal capacity.
Manufacturing is primarily based on orders and forecasts that are updated each month. Accordingly, the level of obsolescence is insignificant for the company's inventory of finished goods. Whenever there is a replacement of components, the remaining inventory is written down when the replacement occurs. Obsolescence of spare parts is assessed each quarter by analyzing the inventory turnover rate.

Impairment
Impairment testing is done whenever there is the risk of a write-down requirement. It is also performed at least once per year at the year-end closing by calculating the net present value (NPV). NPV is calculated on forecasted cash flows using a discounted cash flow model.
IAS 36 is applied for impairment of assets other than: financial assets that are reported in accordance with IAS 9, available-for-sale assets and disposal groups that are reported in accordance with IFRS 5, inventories and deferred tax assets. For the exempted assets listed above, the carrying amount is assessed in accordance with the applicable reporting standard.
Depreciable assets are tested for impairment whenever events or changes in the conditions indicate that the carrying amount is perhaps not recoverable. Impairment is recognized for the amount that the asset's carrying amount exceeds its anticipated recoverable amount. When testing for impairment, assets are grouped at the lowest levels where there are separate identifiable cash flows (cash flow-generating units).
An impairment loss is reversed if there is both an indication that the need for impairment no longer exists and there has been a change in the assumptions that formed the basis for the calculation of the recoverable amount.

Earnings per share
The calculation of earnings per share is based on the Group's profit (loss) for the year attributable to the Parent Company's owners and using the weighted average number of shares outstanding during the year.
When calculating earnings per share after dilution, earnings and the average number of shares are adjusted to take into account the effects of dilutive potential ordinary shares such as stock options Dilution from options affects the number of shares and arises only when the exercise price is lower than the market price.

Employee benefits
(i) Pension plans
The Group only has defined contribution pension plans. Defined-contribution pension plans are those where the company's obligation is limited to the fees it has committed to paying. For these types of plans, the size of the employee's pension depends on the fees paid by the company to the plan (or to an insurance company) and the return on capital generated by those funds. Consequently, it is the employee who carries the risk that the compensation will be lower than expected, as well as the investment risk, i.e. that the invested assets will be insufficient for providing the expected benefits. The company's obligations regarding fees for defined contribution plans are reported as an expense in profit or loss for the year at the rate they are earned by the employees performing services for the company during the period.

(iii) Share-based remuneration to employees
The Group has warrant schemes for employees in Sweden and warrants for the Board of Directors. They are acquired by employees and Board members at a market-based price. There are also stock option programs for employees in the USA which are issued free of charge. See Note 25 for more information. These are reported in accordance with IFRS 2.
In May 2023, the extraordinary general meeting resolved to set up stock option plans, issued free of charge, to staff in the USA (23/26 1-2) and reported in accordance with IFRS 2. At the AGM in September 2023, it was resolved to set up a share savings program for employees (23/26:3) and the Board (23/26:4) for the Swedish company and reported in accordance with IFRS 2 after allocation. A resolution was also passed on stock options for employees at the US subsidiary, to be issued free of charge to employees in the USA (23/26 5-6) and reported in accordance with IFRS 2 after allocation. The programs from the AGM (23/26: 3-6) were never issued however, because the share price trend was negative. The fair value of stock option and share saving plans is determined at the time of granting the right. The value is reported as a payroll expense in the income statement, allocated over the earnings period, with a corresponding increase in equity. The recognized cost corresponds to the fair value of the number of options or shares expected to be earned. In subsequent periods, this cost is adjusted to reflect the actual number of earned stock options.
The associated social security contributions are expensed, along with a liability that is regularly revalued based on changes in the fair value of the options.

Parent Company accounting policies
The Parent Company's annual report has been prepared in accordance with the Annual Accounts Act (1995:1554) and RFR 2 Accounting for Legal Entities, issued by the Swedish Financial Reporting Board. The interpretations pertaining to listed companies that have been issued by the Swedish Financial Reporting Board have also been applied. The application of RFR 2 means that in the annual report for the legal entity, the Parent Company applies all of the IFRS adopted by the EU and the interpretations, to the extent possible without deviating from what is stipulated in the Annual Accounts Act, the Pension Obligations Vesting Act and with consideration given to the relationship between accounting and taxation. The recommendation states which exceptions from, and additions to, IFRS should be made.

(i) Differences between the Group's and the Parent Company's accounting policies
Differences between the Group's and the Parent Company's accounting policies are presented below. The accounting policies presented below for the Parent Company have been applied consistently in all periods presented in the Parent Company's financial statements.

(ii) Classification and presentation
For the Parent Company, both an income statement and statement of other comprehensive income are provided. For the Group, these two reports are what comprises the consolidated statement of comprehensive income.
Furthermore, for the Parent Company, the names of its reports are "balance sheet" and "statement of cash flows". The corresponding reports for the Group are called "consolidated statement of financial position" and "consolidated statement of cash flows". For the Parent Company, the income statement and balance sheet have been presented in accordance with the Annual Accounts Act. However, the statement of other comprehensive income and statement of changes in equity have been prepared in accordance with IAS 1 Presentation of Financial Statements and the statement of cash flows has been prepared in accordance with IAS 7 Statement of Cash Flows.
Differences between the consolidated financial statements and the Parent Company's income statement and balance sheet primarily pertain to reporting of financial income and expenses, fixed assets, equity and the fund for development expenditure. Also, provisions are reported as a separate heading in the Parent Company's balance sheet.

(iii) Subsidiaries
Shares in subsidiaries are reported in the Parent Company according to the cost method. This means that transaction costs are included in the carrying amount of holdings in subsidiaries. In the consolidated financial statements, transaction costs are reported directly in profit or loss as incurred.

(iv) Group contributions and shareholder contributions
The Parent Company thus reports both Group contributions paid and received as appropriations. Shareholder contributions made are reported as an increase in the value of shares and participations. An assessment is then made as to whether there is a need to record an impairment loss on the value of shares and participations in question.

(v) Leased assets
In the Parent Company all leased assets are expensed on a straight-line basis over the lease term.

(vi) Borrowing costs
In the Parent Company, borrowing costs are reported in profit or loss in the period they arise. No borrowing costs are capitalized on assets.

(viii) Fund for development expenditure
Capitalized costs for development work are recognized in the Parent Company financial statements as part of equity in the fund for development expenditure, which reduces non-restricted equity.

NOTE 3 FINANCIAL RISK MANAGEMENT AND CAPITAL RISK

Financial risk management
The Group's business activities are associated with a variety of financial risks: market risk (including currency risk and interest rate risk on cash flows), credit risk and liquidity risk. The Group's overall risk management policy, which has been established by the Board, is to strive for minimal adverse effects on financial results and financial position.

Market risk
Currency risks
The Group has operations both domestically (in Sweden) and internationally, which means that there is exposure to fluctuations in different currencies, particularly USD and EUR. Currency risk arises through future business transactions and reported assets and liabilities. Biovica does not currently have a policy for hedging its currency exposure. If the SEK had weakened/strengthened by 1% during the financial year, all other variables held constant, the recalculated earnings after tax as of 30 April 2024 would have been SEK 13 (23) thousand lower/higher. The corresponding effect on the Parent Company would be SEK 13 (23) thousand.

Interest rate risk on cash flows
Interest rate risk is the risk that the value of financial instruments will fluctuate due to changes in market interest rates. The Group currently only has interest-bearing financial assets, primarily in the form of bank balances. Only a small portion of liquid assets are invested in securities. Calculated on the basis of financial interest-bearing assets and liabilities with variable interest as of April 30, 2024, a change in the market interest rate of one percentage point would affect the Group's and the Parent Company's earnings by SEK 128 (122) thousand.

Credit risk
Credit risk is the risk that a party to a transaction involving a financial instrument is unable to fulfill its obligation. The maximum exposure to credit risks associated with financial assets amounted to SEK 1,667 (577) thousand on April 30, 2024. The corresponding figure for the Parent Company was SEK 1,066 (782) thousand.

Liquidity risk
Conservatism in managing liquidity risk involves holding sufficient liquid funds or agreed credit facilities in order to be able to run the business. Based on the current business plan, liquidity is sufficient for running the business through the middle of 2025 provided that the outcome of TO3B is as planned. If that does not happen, there is a risk that liquidity will not be sufficient for getting the company to the point when it is cash flow positive, which means that the necessary funding for continued operations over the next 12 months has not been secured. The management team is currently evaluating various funding opportunities for the company and has concluded that there are good options for solutions during fall 2024 that guarantee the company's ability to continue as a going concern.

The maturity structure for the Group's financial liabilities is presented below.

	Within 3 months	Between 3 months and 1 year	Between 1 and 2 years	Between 2 and 5 years	More than 5 years
Accounts payable	3,028	–	–	–	–
Accrued liabilities	20,303	–	–	–	–
	23,331	**0**	**0**	**0**	**0**

Managing capital risks
The Group's goals pertaining to capital structure (defined as equity), are to ensure that the company is able to run its operations in order to generate returns for its shareholders and value to other stakeholders, along with ensuring that the capital structure is optimal with regard to the cost of the capital. Dividends to shareholders, redemption of shares, issuance of new shares or sale of assets are examples of measures that the company can use to adjust the capital structure.

The Group's debt/equity ratio

SEK thousands	2023/2024	2022/2023
Total interest-bearing liabilities	7,828	7,304
Less: interest-bearing assets	79,407	114,325
Net debt	**71,579**	**107,020**
Total equity	96,640	138,636
Net debt-equity ratio (%)	74	77

Net debt-equity ratio
Net debt divided by equity.

NOTE 4 IMPORTANT ESTIMATES AND ASSESSMENTS FOR ACCOUNTING PURPOSES

Described below are the most important assumptions about the future, and other significant sources of uncertainty in estimates as of the closing date that entail a significant risk of needing to make material adjustments to the carrying amounts of assets and liabilities during the next financial year. The most significant uncertainty is associated with intangible assets.

Intangible assets
Capitalization of intangible assets only occurs when all of the criteria listed in Note 2, Intangible assets, have been met. Impairment testing is based on a review of the recoverable amount, which is assessed based on the value-in-use of the asset concerned. The company's senior executives calculate future cash flows based on internal business plans and forecasts. The budget/business plan is for the next financial year and the forecast period is the budget +9 years.
This also involves making estimates on such things as discount rates and future rates of growth that extend beyond adopted budgets and forecasts. The carrying amount of the Group's intangible assets amounts SEK thousands 31,602 (37,420) thousand, of which SEK 29,400 (34,488) thousand is capitalized development expenditure and SEK 2,202 (2,932) is patents. Changes in the assumptions made by the company's senior executives when testing for impairment could have a significant impact on the company's reported earnings and financial position.

Internal development expenditure for research and development
Assessment is required for making the allocation between the research and development phases in new development projects of diagnostic tests. Assessments must also be made when deciding whether the requirements for capitalizing development expenditure have been met. After capitalization occurs, management monitors that the accounting requirements for development costs are still being met, along with whether there is any indication of impairment to the capitalized expenditure. Management continuously evaluates that the financing is secured.

Growth and gross margin
The recoverable amount is based on a calculation of the value-in-use by using cash flow forecasts based on budgets that have been approved by the Board of Directors, along with forecasts that stretch over the life of the company's patents. The forecasts are based on the business plan for 2024/2025. Gross margin is calculated based on the product calculation.

WACC (weighted average cost of capital)
WACC represents a weighted average of the risk that both owners and the financial market are prepared to take in order to finance operations. When calculating the WACC, consideration is given to the fact that operations have been financed via both debt and equity. The cost of equity is based on expectations of a certain return on invested capital in the financial market. The cost of debt capital is based on borrowing costs in the financial market. The WACC rate corresponds to the Group's assessed average cost of capital and it is primarily set using the Group's yield requirement. Added to that is an estimation of the market's assessment of risk. Changes between the years in the WACC rate are attributable to such things as changes in the level of debt. For impairment testing at year-end, a WACC rate of 31.27% after tax is used.

Impairment of non-financial assets
Property, plant and equipment, along with intangible assets that are depreciated/amortized, are tested for impairment whenever events or changes in the conditions indicate that the carrying amount is perhaps not recoverable. Impairment is recognized for the amount that the asset's carrying amount exceeds its recoverable amount. The recoverable amount is equal to the asset's fair value less selling costs or its value-in-use (whichever is higher). When testing for impairment, assets are grouped at the lowest levels where there are separate identifiable cash flows (cash-generating units).
An impairment loss is reversed if there is both an indication that the need for impairment no longer exists and there has been a change in the assumptions that formed the basis for the calculation of the recoverable amount. A reversal is only made to the extent that the asset's carrying amount after reversal does not exceed the carrying amount that would have been reported (less depreciation, where applicable) if no write-down had been made.

Useful life of depreciable assets
At each closing date, management reviews its assessments of the useful life that has been established for each category of depreciable assets, taking into consideration how long the Group expects to use those assets. There is uncertainty in these assessments because of the demand and market acceptance.

NOTE 5 NET SALES

All net sales are sales at a particular point in time. No sales are reported as sales over time. Net sales are distributed across the following lines of business for the Group and Parent Company:

	2023/2024	2022/2023
Goods	4,236	2,200
Services	3,054	1,184
	7,290	**3,383**

Net sales are distributed across the following geographic markets for the Group and Parent Company:

	2023/2024	2022/2023
Sweden	41	–
EU, excl. Sweden	1,369	125
USA	5,583	3,258
Asia	297	–
	7,290	**3,383**

NOTE 6 SEGMENT REPORTING

Operating segments are reported in a manner consistent with internal reporting provided to the chief operating decision maker. The chief operating decision maker is the function that is responsible for allocating resources and assessing the operating segments' performance. In the Group, this function has been identified as the senior management team, which consists of six people including the CEO. Senior management has determined that the Group, as a whole, is a single segment based on the information that the Board and senior management together use as the basis for allocating resources and evaluating performance. Sales are analyzed however in accordance with the table below. The Group's net sales consist of the sale of goods and services, which are primarily invoiced from Sweden. IVD tests are invoiced from Biovica Inc. in the USA. Customers are primarily in the USA.

Net sales are derived from the following product groups:

	2023/2024	2022/2023
IVD test	788	–
Research Test	4,502	1,082
Research Kit	2,000	2,301
	7,290	**3,383**

NOTE 7 INTRA-GROUP PURCHASES AND SALES

Biovica International AB purchases sales support and other services from its subsidiary, Biovica Inc. During the year, such services were purchased for an amount of SEK 91,561 (61,884) thousand. Biovica International AB sells diagnostic kits to Biovica Inc. During the year, sales of such kits amounted to SEK 21,463 (7,434) thousand.

NOTE 8 OTHER OPERATING INCOME

	The Group		Parent Company	
	2023/2024	2022/2023	2023/2024	2022/2023
Grants	6	254	6	254
Gain on disposal of fixed assets	–	83	–	83
Foreign exchange gains/losses	786	383	786	383
Other remuneration and income	222	18	222	18
	1,013	**739**	**1,013**	**739**

Grants are EU grants that have been received. The income from grants to projects is recognized at the rate that the associated project is completed.

NOTE 9 AUDIT EXPENSES

	The Group		Parent Company	
	2023/2024	2022/2023	2023/2024	2022/2023
Grant Thornton Sweden AB				
Audit assignment	-873	-662	-779	-643
Audit activities besides the audit assignment	-485	-809	-485	-809
	-1,358	**-1,471**	**-1,264**	**-1,452**

Audit refers to the statutory audit of the annual report and accounts, along with the Board's and CEO management. It also includes other work that the company's auditor deems necessary, advice and other assistance resulting from observations made during the audit or execution of other such tasks. Everything else is other services.

NOTE 10 NUMBER OF EMPLOYEES, GENDER DISTRIBUTION, EMPLOYEE BENEFIT EXPENSES AND REMUNERATION TO SENIOR EXECUTIVES

	The Group		Parent Company	
	2023/2024	2022/2023	2023/2024	2022/2023
Average number of employees				
Women	18	14	15	11
Men	18	17	9	11
	37	**31**	**24**	**22**
Gender distribution, senior executives				
Women	2	2	2	2
Men	3	5	3	5
	5	**7**	**5**	**7**
Gender distribution, Board of Directors				
Women	3	3	3	3
Men	4	5	4	5
	7	**8**	**7**	**8**
Employee benefit expenses				
Salaries and other benefits to the Board of Directors	1,638	1,810	1,638	1,810
Salaries and other benefits to the CEO	2,519	2,399	2,519	2,399
Salaries and other benefits to other senior executives (5 people)	7,817	8,377	7,817	8,377
Salaries and other benefits to other employees	52,053	33,254	10,426	9,038
Social security contributions	10,785	6,955	6,749	5,808
Pension expenses for the Board and CEO	462	482	462	482
Pension expenses for other senior executives	1,078	1,127	1,078	1,127
Pension expenses for other employees	1,028	920	1,028	883
Total salaries, other benefits, social security contributions and pension contributions	**77,379**	**55,324**	**31,717**	**29,925**

Remuneration to the Board of the Parent Company

	2023/2024	2022/2023
Lars Holmqvist, Chairman of the Board	481	480
Maria Holmlund	263	250
Ulf Jungnelius	219	200
Jesper Söderqvist	250	230
Henrik Osvald	125	250
Marie-Louise Fjällskog	100	200
Annika Berg	200	200
Anders Rylander*	-	-
	1,638	1,810

* Anders Rylander is employed as the CEO of Biovica and therefore does not receive any Board fees.

Employee benefit expenses for Biovica's US subsidiary amount to SEK 50,717 (36,574) thousand, which is comprised of salary, social security contributions and pension expensions. There are no agreements in place on severance pay. For the CEO, the notice period is six months.

NOTE 11 FINANCIAL INCOME AND FINANCIAL EXPENSES

The Group	2023/2024	2022/2023
Financial income		
Exchange rate differences	1,839	–
Interest income	1,159	271
Total financial income	**2,998**	**271**
Financial expenses		
Exchange rate differences	–	-212
Interest expenses	-4	0
- financial leasing, dissolution of discounting effect	-285	-281
Total financial expenses	**-289**	**-493**
Profit (loss) from financial items, net	**2,709**	**-222**

Parent company	2023/2024	2022/2023
Other interest income and similar profit or loss items		
Exchange rate differences	1,112	–
Interest income, Group companies	69	210
Interest income	1,157	271
Total interest income and similar profit or loss items	**2,338**	**480**
Interest expenses and similar profit or loss items		
Exchange rate differences	–	-160
Interest expenses	0	0
Total interest expenses and similar profit or loss items	**0**	**-160**
Profit (loss) from financial items, net	**2,338**	**321**

NOTE 12 TRANSACTIONS WITH RELATED PARTIES

During the year, the company, represented by parties related to the main owner and board member, Anders Rylander, leased office facilities to the Parent Company. The total fee for rent paid was SEK 271 (230) thousand. The transactions were on market-based terms and conditions.

NOTE 13 TAX EXPENSE

The Group	2023/2024	2022/2023
Profit (loss) before tax	-124,073	-110,680
Tax according to the applicable tax rate 20.6% (20.6%)	25,559	22,800
Tax effect of non-capitalized loss carryforwards	-29,468	-27,615
Tax effect of non-deductible expenses	-114	-187
Tax effect of non-taxable income	0	0
Tax effect of unrecognized non-deductible expenses	3,611	5,188
Effect of foreign tax rates	-275	1
Reported tax	**-687**	**187**
The tax expenses is comprised of the following:		
Current tax expense	-676	-709
Deferred tax revenue		
– Change in temporary differences	-11	896
Tax expense	**-687**	**187**
Deferred tax revenue reported in other comprehensive income	-11	896

Parent Company	2023/2024	2022/2023
Profit (loss) before tax	-126,363	-109,800
Tax according to the applicable tax rate	26,031	22,619
Tax effect of non-capitalized loss carryforwards	-29,463	-27,605
Tax effect of non-deductible expenses	-179	-201
Tax effect of non-taxable income	0	0
Tax effect of unrecognized non-deductible expenses	3,611	5,187
Reported tax	**0**	**0**

Note 18 contains information on deferred tax assets.

NOTE 14 CAPITALIZED EXPENDITURE FOR DEVELOPMENT AND SIMILAR WORK

Group and Parent Company	2024-04-30	2023-04-30
Opening cost	53,857	52,284
Capitalized expenditure	–	1,573
Closing accumulated cost	**53,857**	**53,857**
Opening amortization	-19,370	-15,593
Amortization for the year	-5,088	-3,777
Closing accumulated amortization	**-24,458**	**-19,370**
Closing carrying amount	**29,400**	**34,488**

In addition, SEK 0 (1,573) thousand was expensed for research during the year.
The intangible assets are comprised in part of capitalized expenditure for the development effort behind DiviTum TKa , which was launched in the clinical market in the USA subsequent to receiving FDA approval. It is also comprised of capitalized expenditure for the development of a new version of DiviTum®TKa to measure thymidine kinase activity (TKa). Amortization of the capitalized expenditure started as soon as sales of DiviTumTKa to the research market began. That occurred in August 2020. The remaining amortization period for DiviTumTKa is approximately 6 years.

NOTE 15 PATENTS

Group and Parent Company	2023-04-30	2022-04-30
Opening cost	9,896	9,896
Closing accumulated cost	**9,896**	**9,896**
Opening amortization	-6,964	-6,234
Amortization for the year	-729	-729
Closing accumulated amortization	**-7,693**	**-6,964**
Closing carrying amount	**2,203**	**2,932**

Patents consist of the costs incurred to protect the rights to innovation of measuring thymidine kinase activity (TKa) via various versions of DiviTum TKa. The remaining amortization period is between 3-6 years.

NOTE 16 MACHINERY, EQUIPMENT, TOOLS, FIXTURES AND FITTINGS

	The Group		Parent Company	
	24-04-30	23-04-30	24-04-30	23-04-30
Opening cost	4,737	3,550	3,751	3,550
Purchases	146	1,206	146	201
Translation differences	67	-19	–	–
Closing accumulated cost	**4,950**	**4,737**	**3,897**	**3,751**
Opening depreciation	-3,402	-2,917	-3,249	-2,917
Depreciation for the year	-354	-487	-149	-331
Translation differences	-15	3	–	–
Closing accumulated depreciation	**-3,771**	**-3,402**	**-3,397**	**-3,249**
Closing carrying amount	**1,179**	**1,336**	**499**	**502**

NOTE 17 LEASING

The Group has lease agreements that are primarily for premises and cars. Leases where the underlying asset is of low value pertain to office equipment and amount to SEK 18 (18) thousand for the year. The Group does not have any short-term leases. Total cash flow for leasing amounts to SEK 146 (1,206) thousand. Interest expense on lease liability for the year amounts to SEK 285 (281) thousand.

The Group	2024-04-30	2023-04-30
Opening cost	15,723	15,991
Translation differences	343	329
Sales/disposals	–	-597
Closing accumulated cost	**16,066**	**15,723**
Opening amortization	-5,848	-2,986
Translation differences	-26	-26
Sales/disposals for the year	–	385
Amortization for the year	-3,257	-3,221
Closing accumulated amortization	**-9,131**	**-5,848**
Closing carrying amount	**6,935**	**9,875**

Right-of-use assets

	2024-04-30	2023-04-30
Premises	6,464	9,310
Cars	471	565
	6,935	**9,875**

Depreciation of right-of-use assets

	2024-04-30	2023-04-30
Premises	-3,163	-3,077
Cars	-94	-144
	-3,257	**-3,221**

The present value of liabilities associated with right-of-use assets is:

	2024-04-30	2023-04-30
Within 1 year	3,532	3,149
Between 1- 5 years	4,296	7,304
More than 5 years	–	–
	7,828	**10,453**

The Parent Company's leasing costs
Leases where the company is lessee

Expensed lease payments for the year:

Parent Company	2023/2024	2022/2023
Total leasing costs	2,734	2,622
	2,734	**2,622**

Leased office space and rental of office equipment are classified as operating leases. Most of the leasing costs are attributable to rental of office space via operating leases. The leasing agreements run without special restrictions with an option for extension.

NOTE 18 DEFERRED TAX ASSET

The Group has tax loss carryforwards that may be utilized against taxable profits in the future. The company reports a deferred tax asset when it is probable that taxable profits will be generated, Capitalization of deferred tax would result in a deferred tax asset of SEK 99 million as of 2024-04-30. However, the company's executive management team has concluded that the prerequisites do not yet exist for reporting a deferred tax asset. As of 30 April 2024, the Group's tax loss carryforwards amounted to SEK 481,810 (354,316) thousand.
The deferred tax asset is attributable to right-of-use agreements.

Deferred tax asset

	2024-04-30	2023-04-30
Opening cost	3,668	2,728
Change for the year	-541	940
Closing carrying amount	**3,127**	**3,668**

Deferred tax liability

	2024-04-30	2023-04-30
Opening cost	2,710	2,666
Change for the year	-530	44
Closing carrying amount	**2,180**	**2,710**

NOTE 19 GROUP COMPANIES

	2024-04-30	2023-04-30
Opening cost	108	108
Closing accumulated cost	108	108
Closing carrying amount	**108**	**108**

Name/Registered office	Registered office	CIN	Number of shares	Share %	Carrying amount (SEK)
Biovica Services AB	Uppsala	556781-8454	1,000	100%	100,000
Biovica Inc.	Delaware, USA	30-1045327	100	100%	8,236

	Equity (SEK)	Profit/loss (SEK)
Biovica Services AB	371,190	-24,484
Biovica Inc	5,454,361	1,271,810

NOTE 20 RECEIVABLES FROM GROUP COMPANIES

	2024-04-30	2023-04-30
Opening cost	9,911	4,788
Additional receivables	24,941	17,113
Payments for the year	-27,354	-11,990
Closing accumulated cost	**7,498**	**9,911**
Closing carrying amount	**7,498**	**9,911**

NOTE 21 PREPAID LEASE PAYMENTS, PARENT COMPANY

Prepaid lease payments

	2024-04-30	2023-04-30
Opening cost	95	117
Sales/disposals	–	-22
Closing accumulated cost	**95**	**95**
Opening amortization	-95	-76
Amortization for the year	–	-19
Closing accumulated amortization	**-95**	**-95**
Closing carrying amount	**0**	**0**

NOTE 22 SHARES

Biovica has issued both Class A shares (each worth 3 votes) and Class B shares (each worth 1 vote). As of 30 April 2023 there was a total of 84,055,560 shares; of which 6,271,293 Class A shares and 77,784,267 Class B shares. The Class A shares are unlisted and the Class B shares are listed on First North Premier. Share capital amounted to SEK 5,603,704 and the quotient value per share is SEK 0.07. The total number of votes amounted to 96,598,146.

Reclassification of shares

At the end of each quarter, class A shareholders are offered the opportunity of reclassifying their shares to B shares. During the year, no reclassification of Class A shares occurred.

2024-04-30	Class A shares	Class B shares	Total
2023-05-01	6,271,293	39,470,101	45,741,394
Reclassification	-	-	-
New share issue		38,314,166	38,314,022
After reclassification	**6,271,293**	**77,784,267**	**84,055,560**

NOTE 23 SHARE CAPITAL AND OTHER CONTRIBUTED CAPITAL

	Number of shares	Share capital	Other contributed capital	Total
Opening capital on 1 May 2017	**17,573,372**	**1,172**	**133,776**	**134,948**
Closing balance, 30 April 2018	**17,573,372**	**1,172**	**133,776**	**134,948**
Closing balance, 30 April 2019	**17,573,372**	**1,172**	**133,776**	**134,948**
New share issue	6,000,000	400	56,282	56,682
Reclassification	–	–	5,074	5,074
Closing balance, 30 April 2020	**23,573,372**	**1,572**	**195,132**	**196,704**
New share issue	4,700,000	313	147,737	148,050
Issue fees	–	–	-7,151	-7,151
Warrants	145,000	10	3,040	3,050
Closing balance on 30 April 2021	**28,418,372**	**1,895**	**338,758**	**340,653**
Warrants	70,000	4	1,196	1,200
Share-based payments, employees	–	–	94	94
Closing balance, 30 April 2022	**28,488,372**	**1,899**	**340,049**	**341,948**
New share issue	17,153,022	1,145	147,572	148,717
Issue fees	–	–	-25,177	-25,177
Warrants	100,000	5	1,367	1,372
Share-based payments, employees	–	–	127	127
Closing balance, 30 April 2023	**45,741,394**	**3,049**	**463,938**	**466,987**
New share issue	38,314	2,554	96,566	99,121
Issue fees	–	–	-16,650	-16,650
Warrants	–	–	–	–
Share-based payments, employees	–	–	64	64
Closing balance, 30 April 2024	**84,055,560**	**5,604**	**543,918**	**549,521**

NOTE 24 SHARE PREMIUM RESERVE

The amount received for issued shares over and above the quotient value (share premium) is included in the item Share premium reserve, after a deduction for registration fees and other similar fees, as well as a deduction for applicable tax benefits. The costs for new share issue that have been reported directly in equity amounted to SEK 16,650 (25,177) thousand.
Share premium has also been reported for the issue of share capital pertaining to share-related remuneration to employees, see Note 25.

NOTE 25 WARRANTS

Biovica has 9 outstanding long-term incentive plans for employees and the Board. The warrants were transferred following market valuation in accordance with the Black & Scholes pricing model. A market-based price is used for receipt and payment of warrants. More information is provided in the section, Stock option programs.
The company also has a series of warrants, TO3B, for shareholders that participated in the rights issue in December 2023. More information is provided in the section, Warrants TO3B.

Subscription rights TO3B
In December 2023, a total of 38,314,166 Class B shares were subscribed for in conjunction with the rights issue. The subscription price was SEK 2.61. In total, the company's share capital increased because of the rights issue by SEK 2,554,278, generating approximately SEK 100 million for the company before issue costs. Shareholders who participated in the rights issue were issued free-of-charge an additional 5 warrants of series TO3B for each share they subscribed for. One (1) warrant from series TO3B entitles the holder to subscribe for one (1) newly issued share during during the period 12 September 2024 through 30 September 2024. The subscription price is SEK 2.61. If all warrants from series TO3B are fully exercised, the company's share capital would increase by SEK 1,161,035 generating an additional SEK 45.4 million before issue costs. For more details on TO3B, please see the prospectus for the rights issue, which is published on the company's website.

Employee stock option program
At the EGM on 17 May 2023, it was resolved to implement two new incentive programs for employees working at the company's US subsidiary. The Employee Stock Option Program 2023/2026 consists of 168,000 stock options issued free of charge to employees. Performance Share Program 2023/2026 consists of 56,000 performance shares issued to free of charge to employees. Vesting of the allocated stock options and performance shares is as follows: 1/3 vesting on 1 September 2024; and then 1/8 in linear quarterly installments through 31 August 2026. These stock options are earned on the condition that the participant is still an employee of the company and has not submitted notice of termination of their employment as of the dates when those options are earned. In the case where a participant is no longer an employee of the company, or has submitted notice of termination of their employment prior to the earnings date, any stock options already earned may be exercised on the scheduled earnings date in accordance with what is stipulated below, but no additional options will be earned. Each earned employee stock option entitles the holder to acquire one share in the company at a price of SEK 10.13. Each performance share entitles the holder to receive one share free of charge if the performance condition is met. In order to meet the performance target, the average annual growth rate of the Biovica share price must be at least 14 percent per year during the program. The average CAGR shall be measured by comparing the volume-weighted average price paid for shares in Biovica during the 20 trading days after the 2023 AGM to the volume-weighed average price paid for shares in Biovica during the corresponding period in 2026, which corresponds to SEK 10.12 at the end of the program.
At the 2023 AGM, it was decided to implement four new incentive programs. 2023/2026:3, 2023/2026:4, 2023/2026:5 and 2023/2026:6. These programs were never awarded due to an unfavorable stock price trend. As of the closing date, the company had 1,556,927 options outstanding from the employee long-term incentive program. A total of 241,664 of the stock options had been earned, a total of 235,336 unearned but still possible to earn and the remainder expired since the person they had been allocated to had left the company.

Dilution
If the existing warrant schemes and employee stock option program are fully utilized, it will result in a total of 1,556,927 shares being issued, which corresponds to dilution of approximately 1.85 of the company's fully diluted equity and votes, calculated on the number of shares that would be added if all warrants and stocks are exercised in each of the programs.

Program	To	Class B shares	Subscription price	Warrant price	Subscription period	Share capital increase	Number of class B shares
TO8	employees	241,648	70.35	2.61	25 March 2023 – 25 August 2024	16,110	241,648
PO9	employees	134,825	70.35	-	25 March 2023 – 25 August 2024	8,998	134,825
TO10	Board of Directors	124,454	70.35	3.94	1 August 2025 – 30 September 2025	8,297	124,454
23/26:1	employees	240,000	10.13	-	1 June – 30 September 2026	16,000	240,000
23/26:2	employees	56,000	10.12	-	1 July 2023 – 15 September 2026	3,733	56,000
23/26:3	employees	358,000	7.49-12.62	-	1 October – 1 November 2026	23,867	358,000
23/26:4	Board of Directors	195,000	7.49-12.62	-	1 October – 1 November 2026	13,000	195,000
23/26:5	employees	155,250	12.66	-	1 October – 1 November 2026	10,350	155,250
23/26:6	employees	51,750	11.10	-	15 September – 1 November 2026	1,333	51,750
		1,556,927				**103,795**	**1,556,927**

NOTE 26 NON-CASH ITEMS

	The Group		Parent Company	
	2023/2024	2022/2023	2023/2024	2022/2023
Profit or loss from divested right-of-use assets	–	18	–	–
Warrants scheme	64	127	64	127
Currency effects	303	-139	322	-59
	367	**7**	**385**	**68**

NOTE 27 PLEDGED ASSETS

	2024-04-30	2023-04-30
Pledged assets	None	None

NOTE 28 CONTINGENT LIABILITIES

	2024-04-30	2023-04-30
Contingent liabilities	None	None

NOTE 29 CASH AND CASH EQUIVALENTS

	The Group		Parent Company	
	2023/2024	2022/2023	2023/2024	2022/2023
Bank balances	66,565	102,122	64,263	93,801
Short-term investments	12,842	12,205	12,842	12,205
	79,407	**114,327**	**77,105**	**106,006**

NOTE 30 FINANCIAL ASSETS AND LIABILITIES

The accounting policies contain a description of each category of financial assets and liabilities, the accounting policy for each and how they are measured. The carrying amounts for financial assets and liabilities, by category, is as follows:

Amortized cost, SEK thousand

	The Group	Parent Company
Financial assets	**2023/2024**	**2023/2024**
Accounts receivable	1,667	1,066
Other current receivables	1,659	607
Accrued income	527	527
Cash and cash equivalents	66,565	64,263
Total financial assets	**70,418**	**66,463**

Other financial liabilities	**2023/2024**	**2023/2024**
Other non-current liabilities	4,296	–
Accounts payable	3,028	1,486
Accrued expenses and deferred income	20,303	10,323
Other current liabilities	4,713	977
Total financial liabilities	**32,340**	**12,786**

Amortized cost, SEK thousand

	The Group	Parent Company
Financial assets	**2022/2023**	**2022/2023**
Accounts receivable	577	577
Other current receivables	968	871
Accrued income	327	532
Cash and cash equivalents	102,122	93,801
Total financial assets	**103,994**	**95,781**

Other financial liabilities	**2022/2023**	**2022/2023**
Other non-current liabilities	7,304	–
Accounts payable	3,277	1,953
Accrued expenses and deferred income	15,172	7,626
Other current liabilities	4,133	800
Total financial liabilities	**29,886**	**10,378**

Loan receivables and accounts receivable

The Group's operations generate accounts receivable, which, historically, have not totaled significant amounts. Historically, there have not been any bad debt losses on accounts receivable either. Cash & cash equivalents primarily consists of bank balances and short-term investments in SEK. As of the closing date, there were no receivables that needed to be written down. The fair value of the Group's loan receivables and accounts receivable is in all material respects consistent with the carrying amounts.

Borrowings and accounts payable

The Group does not have any interest-bearing liabilities. The maturity structure for financial liabilities is provided in Note 3. The Group has not provided any security for any of the financial liabilities. The fair value of the Group's financial liabilities is in all material respects consistent with the carrying amounts.

Financial instruments at fair value

Information on financial instruments at fair value:

	2023/2024		2022/2023	
Group and Parent Company	Carrying amount	Value change recognized	Carrying amount	Value change recognized
Available-for-sale financial assets	12,842	637	12,205	-172

The financial assets stated above consist of investments in funds. For financial instruments that are listed, the quoted prices are used for measurement at fair value (Level 1).

The Board of Directors' and CEO's assurance

The consolidated income statement and balance sheet will be brought forth at the Annual General Meeting on 17 September 2024 for adoption.

The Board of Directors and CEO affirm that the consolidated accounts have been prepared in accordance with the International Financial Reporting Standards (IFRS) as adopted by the EU and that they provide a true and fair view of the Group's financial position and results. The Parent Company's financial statements been prepared in accordance with generally accepted accounting policies and they provide a true and fair view of the Parent Company's financial position and results. The Board of Directors' report for the Group and parent company provides a true and fair overview of the Group's and Parent Company's operations, financial position and results and also describes material risks and uncertainties faced by the parent company and the companies that comprise the Group.

Uppsala, 28 June 2024

Lars Holmqvist
Chairman of the Board

Annika Carlsson Berg
Board member

Marie-Louise Fjällskog
Board member

Maria Holmlund
Board member

Jarl Ulf Jungnelius
Board member

Jesper Söderqvist
Board member

Anders Rylander
President/CEO, Board member

Our audit report was issued on 28 June 2024

Grant Thornton Sweden AB

Stéphanie Ljungberg
Authorized Public Accountant

Auditor's report

To the general meeting of the shareholders of Biovica International AB (publ)
Corporate identity number 556774 - 6150

REPORT ON THE ANNUAL ACCOUNTS AND CONSOLIDATED ACCOUNTS

Opinions

We have audited the annual accounts and consolidated accounts of Biovica International AB (publ) for the financial year 2023-05-01 – 2024-04-30.

The annual accounts and consolidated accounts of the company are included on pages 39 – 67 in this document.

In our opinion, the annual accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company as of 30 April 2024 and its financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of the group as of 30 April 2024 and their financial performance and cash flow for the year then ended in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU, and the Annual Accounts Act.

The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Material Uncertainty Related to Going Concern

We would like to draw attention to the loss that the parent company reports of 126 363 TSEK for the year that ended 30th of April 2024. We would also want to refer to the comments in the annual report, which under the heading "Financial position", state that the company does not have sufficient working capital to finance the company's operations during the coming fiscal year, and that the board is actively working to solve the need for capital. If the outcome is not as expected, there is a material uncertainty that may cast significant doubt about the company's ability of going concern.

Other Information than the annual accounts and consolidated accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1 – 38 and 70 – 73. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act and, concerning the consolidated accounts, in accordance with IFRS as adopted by the EU. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intend to liquidate the company, to cease operations, or has no realistic alternative but to do so.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.
- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated accounts. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Biovica International AB (publ) for the financial year 2023-05-01 - 2024-04-30 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.
Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.
As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Uppsala June 28th 2024

Grant Thornton Sweden AB

Stéphanie Ljungberg
Authorised Public Accountant

Glossary

Abstract A short summary of a longer document, such as a dissertation or research article. It briefly states the purposes and results of the research. Abstracts are submitted to scientific conferences in order to spread knowledge of new research.

CDK4/6 inhibitors A new type of targeted, selective drugs that have been shown to be effective against several forms of cancers, including hormone receptor-positive breast cancer.

CLIA certification (The Clinical Laboratory Improvement Amendments): a clinical laboratory that has been certified to accept human samples from people in the USA for diagnostic testing. The Center for Medicare and Medicaid Services (CMS) is the regulatory body that grants certification.

Companion Diagnostics Also called CDx. These are diagnostic tests used to identify patients that would likely respond to a specific treatment, as well as to monitor the treatment effect on individual patients. They thus facilitate personalization of treatment.

Estrogen receptor-positive To determine whether a patient might benefit from hormone treatment, the tumor is studied to assess whether receptors for either estrogen or progesterone. If so, it is hormone receptor-positive, which is the case for around 70 percent of all breast cancer tumors. It is primarily estrogen that has a stimulating effect on tumor growth.

Fulvestrant (Faslodex) A drug that is used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression and HR-positive, HER2-negative advanced breast cancer in combination with palbociclib in women with disease progression after endocrine treatment. Fulvestrant is a Selective Estrogen Receptor Degrader (SERD).

Imaging These are methods that currently serve as the cornerstones for diagnostics and treatment planning for essentially all types of solid tumors. It includes computer tomography (CT) scans and other X-ray methods, magnetic resonance tomography (MRT) scans, positron emission tomography (PET) scans and ultrasound.

IVD – In vitro diagnostics (IVD) are generally defined as a product which, regardless of whether they are used alone or in combination, are designed for performing in vitro tests on samples that have been taken from the human body. The main purpose is to obtain information for diagnostic, monitoring or compatibility purposes.

Palbociclib A new type of targeted, selective drug that has been shown to be effective against several forms of cancers, including hormone receptor-positive breast cancer.

Poster session An event held at a congress or conference with an academic or professional focus to present research information in the form of a paper poster that conference participants may view. A poster session is an event at which many such posters are presented.

Posters These are used to summarize information or research and present it in an attractive way as a means of generating interest in publishing it and sparking discussion at events such as scientific conferences.

Predictive Anticipation about what will happen in the future and used in the contexts like the predictive ability of a particular test.

PREDIX study is a randomized trial of neoadjuvant chemotherapy to treat HER2-positive breast cancer that was carried out during the period 2014–2019 at nine Swedish clinics under the supervision of Karolinska Institute (KI).

Prospective studies are used to study the relationship between various risk factors and a particular disease. This type of study follows individuals both with risk factors and without (the control group), for a period of time into the future. At the end of the study, a comparison is made of the percentage that fell ill in each group.

PYTHIA study A clinical study of patients with metastatic breast cancer. The primary aim of the PYTHIA study is to discover potentially innovative biomarkers for the selection of patients to Palbociclib/Fulvestrant treatment.

Reimbursement Compensation for costs (in this context, it is payment from insurance companies to cover treatment costs).

RUO Research Use Only An ROU product is an IVD (In Vitro Diagnostic) product that is in the development stage and may only be used for laboratory research and clinical studies.

SABCS San Antonio Breast Cancer Symposium is an international scientific symposium on breast cancer held each year in December in San Antonio Texas, USA.

Tymidine kinase an enzyme (kinase), subclass of phosphotransferase.

Shareholder information

ANNUAL GENERAL MEETING (AGM)

Biovica's Annual General Meeting will be held on 17 September 2024 in Uppsala. Notice of the AGM will be published on Biovica's website, in Post- och Inrikes Tidningar (gazette) and in SvD (newspaper). The Board of Directors proposes that no dividends should be distributed to shareholders.

Shareholders who would like to participate in the AGM must be registered in the shareholders' register maintained by Euroclear Sweden AB no later than Monday 9 September 2024 and register for the meeting by casting no later than 11 August.

NOMINATION COMMITTEE

The Nomination Committee has been appointed in accordance with the AGM guidelines and its members are: Anna Rylander Eklund, Mats Danielsson and Lars Holmqvist, Chairman of the Board. If you would like to contact the Nomination Committee, please send an email to: ir@biovica.com

FUTURE REPORTING DATES:

AGM	17 September 2024
Interim Report for Q1: May-July 2024/2025	12 September 2024
Interim Report for Q2: August-October 2024/2025	12 December 2024
Interim Report for Q3: November-January 2024/2025	13 March 2025
Interim report for Q4: February-April 2024/2025	19 June 2025

FOR MORE INFORMATION, PLEASE CONTACT:

Anders Rylander, CEO
Phone: +46 (0)18-44 44 835 E-mail: anders.rylander@biovica.com
Anders Morén, CFO
Phone: +46 (0)18-44 44 835 E-mail: anders.moren@biovica.com

biovica.com

BIOVICA®



Treatment decisions with greater certainty

ANNUAL REPORT **2023/2024**

BIOVICA®